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Epithelial cells (ECs) line body surface tissues and provide a physicochemical barrier to
the external environment. Frequent microbial and non-microbial challenges such as those
imposed by mechanical disruption, injury or exposure to noxious environmental substances
including chemicals, carcinogens, ultraviolet-irradiation, or toxins cause activation of ECs
with release of cytokines and chemokines as well as alterations in the expression of
cell-surface ligands. Such display of epithelial stress is rapidly sensed by tissue-resident
immunocytes, which can directly interact with self-moieties on ECs and initiate both local
and systemic immune responses. ECs are thus key drivers of immune surveillance at body
surface tissues. However, ECs have a propensity to drive type 2 immunity (rather than
type 1) upon non-invasive challenge or stress – a type of immunity whose regulation and
function still remain enigmatic. Here, we review the induction and possible role of type
2 immunity in epithelial tissues and propose that rapid immune surveillance and type 2
immunity are key regulators of tissue homeostasis and carcinogenesis.
Keywords: immune surveillance, Type 2 immunity, epithelial cells, tissue homeostasis, carcinogenesis, IgE,
intraepithelial lymphocytes, sterile stress
Epithelial cells (ECs) are the main constituent of tissues lining
body surfaces like the skin, intestine, lungs, and genitourinary
tract. They regulate crucial life processes such as micronutrient
absorption, gaseous exchange, and thermo- and hydro-control
whilst also providing a physiochemical barrier to the external
environment against microbes and a plethora of non-microbial
stressors. ECs are extremely dynamic and versatile cells and it is
becoming increasingly clear that they are also intimately involved
in the induction and regulation of local tissue- and systemic
immune responses. Disruption of epithelial surfaces may there-
fore result in dysregulated body processes and penetrance to
deeper tissues by microbes or noxious moieties. In addition, the
direct response of ECs to tissue disruption strongly affects resi-
dent immunocytes and their subsequent regulation of both local
and systemic innate and adaptive immunity. A growing body of
evidence both from mouse models and human genetics suggest
that EC dysregulation can be a primary cause of pathology in dif-
ferent tissues. Given the multifaceted biological actions of ECs
and the multitude of challenges imposed on epithelial tissues,
it is reasonable to think that ECs in conjunction with tissue-
resident immunocytes possess mechanisms, both immunological
and non-immunological, to maintain healthy barrier homeostasis
and to minimize inflammation and cellular dysregulation. Indeed,
ECs are now known to be highly immunomodulatory by virtue
of the cytokines, chemokines, damage-associated molecular pat-
tern (DAMP) molecules, and major histocompatibility (MHC)
gene products they express; a repertoire that has collectively been
termed the “epimmunome” (1). ECs express pattern-recognition
receptors (PRRs) including toll-like receptors (TLRs), NOD-like
receptors (NLRs), RIG-I-like receptors (RLRs), and a variety of
“NK” receptor ligands, enabling them to respond to a wide variety
of microbial and non-microbial (including self) moieties and dis-
seminate the response to immunocytes. The NLR–inflammasome
complex allows ECs to respond to non-microbial sterile stress
elicited by toxins, irritants, and (for skin keratinocytes) ultraviolet
(UV) light (2); the most pervasive environmental DNA-damaging
agent (3). Thus, ECs express a suite of sensors for detecting differ-
ing insults and challenges at the body surfaces, and an armory
of soluble and cell-surface molecules to direct an appropriate,
restorative response. These epithelial-driven responses in health
sculpt and modulate tissue homeostasis and local tissue immunity,
in a manner that aids morphological tissue homeostasis, restora-
tion of the epithelial barrier following injury, and elimination or
expulsion of microbial and non-microbial insults. Here, we review
how ECs drive immunity at body surfaces and how this is involved
in regulating immune surveillance, tissue immune homeostasis,
and cancer.
EPITHELIAL CELLS AND THEIR RESPONSE TO CHALLENGE
The vast majority of environmental challenges occur at epithelial
surfaces. The repertoire of responses available to ECs to com-
bat these daily challenges is immense. For example, EC-derived
cytokines include IL-1, IL-6, IL-10, IL-18, IL-25, IL-33, TNFα, and
thymic stromal lymphopoietin (TSLP). Pro-IL-1α and pro-IL-1β
are constitutively produced by ECs, particularly skin keratinocytes,
and are secreted following exposure to noxious stimuli or tis-
sue damage. Corneocytes (non-nucleated skin ECs) release IL-1α
in the skin in response to disruption of the outermost surface,
the stratum corneum (4), while UV-irradiation induces IL-1β. In
addition to agonistic effects on tissue macrophages, IL-1α induces
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growth-factor expression from tissue fibroblasts, prompting a
replicative burst in neighboring ECs to repair damage (5). The
pro-inflammatory cytokines IL-6 and TNFα are produced in large
quantities by damaged ECs; the former of which can also be used
as a STAT-3-dependant autocrine growth factor, in healthy and
cancerous epithelium (6). The most robustly expressed cytokines
upon any EC insult however are IL-25, IL-33, and TSLP. In com-
mon, these three cytokines can drive type 2 immune responses,
which thus impart a particular propensity of epithelial tissues to
induce type 2 immunity. Such predisposition of stressed ECs may
underlie the high frequency of allergic and atopic disease at the
skin and mucosal surfaces. However, despite the intense interest
in this area, the cellular and molecular linkage of type 2 immunity
to barrier- and EC disruption is not clearly understood – nor is
the functional role of this type of immunity to EC homeostasis or
immune surveillance yet fully elucidated.
IL-25, also know as IL-17E, is a member of the IL-17 cytokine
family. Despite bearing some amino acid sequence homology to
the best-characterized IL-17 cytokines, IL-17A and IL-17F, IL-25
has divergent biological functions and promotes Th2 rather than
Th17 responses in vivo. IL-25 directly amplifies expression of the
Th-2 mediators IL-4, IL-5, and IL-13, and supports production
of Th2 serum immunoglobulins (7). IL-25 was first reported with
high steady-state mRNA expression in the kidney, and moderate to
low expression in other organs and the peripheral tissue (8). Sub-
sequently, it was found by multiple groups to be important in type
2-mediated immunity to enteric parasites, such as Trichuris muris
(9), and is upregulated in the gut upon EC-sensing of commensal
bacteria (10). The mouse gut parasite Heligmosomoides polygyrus
bakeri elicits the EC-derived cytokine, IL-1β, which suppresses
IL-25 and IL-33 and promotes pathogen chronicity by attenu-
ating expulsive type 2 responses (11), suggesting that IL-25 is
particularly important in maintaining immunity to gut pathogens.
Similarly, mice and humans subjected to parenteral nutrition have
impaired mucosal immunity, due to reduced gut luminal levels of
antimicrobial effectors, but administration of exogenous IL-25 to
parenteral nutrition-fed mice was found to be protective against
enteric bacterial invasion (12). In allergic models, IL-25 expres-
sion is upregulated upon exposure to allergens both in murine
or human lung EC lines and in primary murine lung ECs (13).
Elevated protein levels have also been found in tissues of patients
with allergic disease in the lung and skin (14). IL-25 has been
found to drive tissue (airway) remodeling, and expression of the
other major EC cytokines IL-33 and TSLP in a house dust mite
model of allergy (15), and drive pulmonary fibrosis by inducing
IL-13 expression from lung innate lymphoid cells (ILCs) in mice
challenged with lung Schistosoma mansoni eggs (16). In addition
to production by ECs, dermal dendritic cells (DCs) have been
reported to be a major source of IL-25 in atopic dermatitis (AD)
patients (17), while IL-25 and IL-33-activated ILC2s in mouse
skin promote AD-like inflammation (18). These reports and oth-
ers highlight an interesting crosstalk and autocrine regulation of
EC-derived effectors, as well as a role for IL-25 in augmenting
epithelial barrier immunity, or conversely promoting pathological
Th2 tissue inflammation, in differing settings.
IL-33 is a multi-functional protein. The full length protein
is localized in the nucleus but following cleavage the c-terminal
fragment acts as a cytokine which binds the receptor ST2. IL-
33 was recently discovered as an IL-1 family member with type
2-promoting functions similar to IL-25. It is expressed by ECs,
macrophages, DCs, and mast cells in vivo and its cytokine func-
tion drives IL-4, IL-5, and IL-13 expression and differentiation of
Th2 CD4+ T cells (19). IL-33-induced IL-4 production appears
to be mainly from innate cells and together these two cytokines
will induce proliferation of B cells and amplify IgE synthesis (20).
Similar to IL-25, IL-33 acts in an autocrine fashion to promote
TSLP expression by ECs, particularly in response to gut nematodes,
where IL-33 mRNA can be detected rapidly following colonization
(21). Interestingly, the efficacy of IL-33 in this infection model (and
others) seems to be highly time-dependent, with administration
of exogenous IL-33 at late time points post-infection being inef-
fective in promoting type 2 responses that would otherwise resolve
infection. IL-33 is highly expressed by intestinal ECs and inflam-
matory infiltrates in ulcerative colitis, with IL-33 cleavage products
being detected in the serum (22). IL-33 is also rapidly released and
detectable in bronchoalveolar lavage fluid following lung allergen
exposure in humans, suggesting it is a rapid type 2 mediator in sites
additional to the gut (23). Protective as well as immunopatholog-
ical roles of EC-derived IL-33 have been described in the skin.
Transgenic over-expression of IL-33 in mouse skin, driven by a
keratinocyte-specific promoter, induces a spontaneous dermatitis-
like disease and activates ILC2s in the dermis (24). It has also
been shown in a phorbol 12-myristate 13-acetate model of skin
inflammation that mice deficient for the IL-33 receptor, ST2, do
not exhibit IL-33-dependant skin inflammation (25). Similarly
in human inflammatory conditions, IL-33 has been reported to be
upregulated in clinical psoriatic lesions and the serum of skin scle-
rosis patients (26). Conversely, mice treated with exogenous IL-33,
following full-thickness skin wounding, demonstrate dramatically
improved wound-healing, collagen deposition, and expression of
extracellular matrix proteins indicative of tissue repair (27). These
reports suggest a particularly rapid and acute role for IL-33 in cuta-
neous homeostasis and gut integrity whereas constitutive, late, or
dysregulated expression may be involved in a variety of chronic
inflammatory conditions. This temporally coordinated aspect fits
well with current thinking of IL-33 as an “alarmin,” whereby its
immediate release from intranuclear stores by damaged, apoptotic,
or necrotic cells rather than a classic Golgi-mediated secretion
pathway (19) facilitates a rapid and restorative response to tissue
damage.
TSLP is produced almost exclusively by ECs of the lung, tonsils,
intestine, and skin (13), and is upregulated in response to tissue
damage (28), various TLR ligands and infection, or exposure to
type 2 cytokines such as IL-4, IL-13, IL25, and IL-33 (29). A pro-
tective role of TSLP in intestinal immunity to T. muris has been
well described; mice which are knockouts for IKKβ fail to produce
TSLP in response to infection, and subsequently develop chronic
intestinal inflammation (30). Mechanistically, EC-derived TSLP
suppresses p40 and upregulates OX40L expression in DCs, a cos-
timulatory molecule with a propensity to license Th2 responses
in CD4+ T cells (31). TSLP also augments Th2 cytokine produc-
tion by direct effects on CD4+ T cells and has indirect, agonist
effects on a variety of granulocyte populations including mast
cells and basophils. Similar to IL-25 and IL-33, inappropriate
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expression or dysregulation of TSLP is implicated in a number
of inflammatory diseases including the triad of atopic diseases;
asthma, allergic rhinitis, and AD (31). TSLP is required for aller-
gic lung inflammation in mice exposed to inhaled antigen, and
TSLP receptor knockout animals do not develop lung inflamma-
tion in this model. Interestingly, these animals do develop strong
Th1 responses with high IFNγ, IL-12, and IgG2a (32), highlight-
ing how a single epithelial-derived molecule can skew adaptive
immune responses in response to tissue-challenge. In humans,
AD sufferers show high TSLP expression in lesional skin (33), and
mice with induced expression of TSLP in the epidermis develop
spontaneous AD-like pathology (34). Production of TSLP is how-
ever critically important for resistance to skin carcinogenesis in
mouse models (35, 36).
Further to cytokines and chemokines, ECs can release other
proteins upon cellular stress. Of note, they can produce hedgehog
morphogens, which are a family of secreted proteins that regulate
a wide variety of physiological processes including tissue devel-
opment during embryogenesis and tissue homeostasis as well as
being implicated in carcinogenesis (37). Sonic Hedgehog h (Hh)
expression was recently found to be upregulated in lung ECs in
models of allergic disease, and lung resident T cells were shown to
respond locally to EC-derived Hh by upregulating IL-4 (38). This
demonstrates that ECs also produce non-classical immune mod-
ulators, such as tissue morphogens, which appear to contribute to
the robust induction of type 2 immunity in epithelial tissues.
In addition to the secreted and soluble molecules produced by
ECs, they also express a variety of cell-surface molecules enabling
them to directly interact with resident and infiltrating immuno-
cytes. For example, ECs express E-cadherin that engage CD103,
which is constitutively expressed on intraepithelial lymphocytes
(IELs) and tissue DCs such as the epidermal Langerhans cells
(LCs). ECs also express T cell costimulatory ligands, although
it remains unclear as to what extent ECs express the classical
B7.1 and 2 molecules, they clearly express PD-L1 and PD-L2
(39). Some members of a novel family of B7-related molecules,
the butyrophilins, appear to be preferentially expressed on ECs
and have been implicated in EC-immune regulation (40) as have
Skint family members which are exclusively expressed on ECs
and have profound impact on IEL development and function
(41, 42). Thus via appropriate receptor–ligand interactions ECs
are capable of initiating and sculpting both local tissue immu-
nity and further downstream systemic immunity. Under condi-
tions of physiochemical tissue disruption or barrier perturbation
(1), infection (43), genotoxic stress (44), sterile inflammation, or
heavy proliferation (45), ECs respond by upregulating additional
self-encoded and cell-surface markers, which are often termed as
“‘stress antigens” as they are indicative of a dysregulated state of
the epithelium. The EC stress antigens have an important role in
initiating and directing tissue immune responses during pertur-
bations and as such these will be discussed in more detail in the
Section “Immune Surveillance” below.
EPITHELIAL CELLS AND THEIR NEIGHBORS
In close association with ECs, the epithelial tissues are home
to several specialized subsets of immunocytes. IELs are found
in all epithelial tissues, but have most notably been studied in
the intestine and skin. IELs are adaptive T cells carrying RAG-
dependent rearranged T cell receptors (TCRs), nevertheless they
are often MHC non-restricted cells and express many innate recep-
tors allowing them to react to stress antigen with “innate-like”
response kinetics. The IELs are a mixture of αβ and γδ T cells,
which are either CD4−CD8− or coexpress a CD8αα coreceptor.
The ratio of αβ to γδ T cells depends on the anatomical site as
well as the species. IEL compartments are often much less diverse
than systemic T cells (for example in the mouse skin and uterus
they are essentially monoclonal), implying that these cells recog-
nize predictable antigens encountered in specific tissues – these
antigens could be either pathogen encoded or self-encoded mol-
ecules that reflect a dysregulated state of the tissue they inhabit.
Not many IEL TCR-specificities have yet been defined, but it seems
clear that both their recognition capabilities and mode of activa-
tion are distinct from systemic T cells (46). Particularly, it has
been proposed that IELs are primarily autoreactive T cells that
have been agonist-selected, recognize tissue stress antigens, and
have regulatory properties (47). The murine skin for example
contains a specialized subset of γδ (TCR)+ IELs called dendritic
epidermal T cells (DETC) that exclusively carry a Vγ5Vδ1 TCR –
a TCR arrangement only found on epidermal IELs (and on the
progenitor fetal thymic population). The skin epithelia also con-
tain a specialized subset of DCs, the epidermal LCs. Both LC and
DETC infiltrate the epithelium very early during stratification of
the skin ECs, and are long-lived and likely self-renewing immune
compartments, which clearly integrate and physically interact with
the ECs.
In addition to the “unconventional” T cells in the epithelium,
more conventional CD8αβ+ αβ T cells have been shown to rapidly
accumulate in tissues upon infection, where they can become
resident memory T cells and provide protective antigen-specific
responses. This was elegantly shown in the skin following local
infection with herpes simplex virus (48) or vaccinia virus (49),
which induced a rapid influx of antigen-specific CD8+ αβ T cells
both into the epithelial epidermal layer and the underlying der-
mis. Interestingly, these infiltrating CD8+ αβ T cells were shown
to populate the entire skin and provide long-lasting protection
against re-infection as a continuing tissue-resident memory T cell
population. In steady state, the subepithelial layer of most tissues
contains a diverse set of immunocytes that can all contribute to
epithelial-immune surveillance. These include tissue-specific res-
ident populations of myeloid cells, such as DC, macrophages and
mast cells, lymphoid cells, such as CD4+ or CD8+ αβ T cells, γδ T
cells, and ILCs, as well as stromal fibroblasts. In fact, it is becoming
increasingly apparent that different tissues constitutively harbor a
variety of specialized immunocytes in the subepithelial space. For
example, in human skin a population of IL-22 and growth factor
producing T cells (Th22) can rapidly enter the epithelium upon
challenge and be involved in epidermal remodeling (50). Similarly,
the gut contains a resident IL-22 producing population of NK-like
cells (51). In recent years, an array of different ILCs has been dis-
covered that are resident in the subepithelial tissue layer. Different
subsets of ILCs dominate in particular tissues and their specialized
functions are starting to be elucidated; many of them contribute to
both homeostatic and pathophysiological conditions in the tissue
they inhabit (52). The subepithelial immunocytes can respond to
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epithelial cues and be recruited into the epithelium upon damage –
in addition systemic immune cells can be recruited both to the
subepithelial and epithelial layer. In sum, the epithelium and body
surface tissues are home to an intricate array of immunocytes,
which can interact and integrate activities in numerous complex
ways that likely differ substantially depending on the anatomical
site and the challenge encountered. Additional research is required
to understand the interaction between different resident immuno-
cytes in the tissues and how their responses may be integrated to
regulate local and systemic immunity.
TYPE 2 IMMUNITY AND ITS TRIGGERS
Epithelial cells and EC-associated leukocytes such as IELs can
clearly drive local and systemic type 2 immunity (53). More con-
ventionally, however, type 2 immunity is thought to be mediated
primarily by Th2 cells, IgE and IgG1 antibodies, as well as a host
of innate immune cells such as mast cells, basophils, eosinophils,
alternatively activated macrophages, and ILCs. The type 2 immune
response in vivo is accordingly extremely heterogeneous and it is
surprisingly poorly understood how type 2 immunity is induced,
regulated – and indeed what its primary physiological function
is. Type 2 immune responses are classically induced by macropar-
asites and conventional thinking holds that type 2 immunity has
evolved to protect against infection by parasites such as helminthes
and ticks. However, this is probably a too simple explanation,
as it is not true that all parasites are fought by IgE and type 2
immunity. Although IgE levels are raised in people as well as mice
with helminth infections, IgE is dispensable for immunity to many
helminthes and much of the IgE raised is not specific to the parasite
(54). Type 2 immunity is also notoriously activated in response to
a broad range of different environmental challenges and antigens.
Such non-infectious stimuli that trigger type 2 immunity are col-
lectively termed allergens and form the basis of a host of allergic
disorders like asthma, allergic rhinitis, food allergies, and AD. Type
2 immune responses have been explored largely in the context of
helminth infections and allergic diseases. They have been thought
to provide a host-beneficial role only as defense against macropar-
asites, whereas allergic reactions are most commonly explained as
a detrimental consequence of a misdirected response mimicking
parasite immunity. This paradigm is now changing and with more
triggers of type 2 immunity being elucidated (Figure 1) it seems
plausible that type 2 immunity can provide host-benefits in set-
tings other than against parasites. In 1991, Profet published an
inspired hypothesis suggesting that the physiological role of aller-
gic responses was an immunological defense against toxins (55).
This idea is resonating with recent data (56, 57) and the hypothesis
has been recharged and expanded into a broader model of inten-
tional allergic host defense not only against helminthes but also
FIGURE 1 | Extrinsic and intrinsic factors promoting type 2 immunity.
Type 2 immunity can be triggered by an array of diverse extrinsic stimuli from
both infectious and non-infectious sources and is most potently induced at
the body surface tissues. Equally, the intrinsic cellular mechanisms inducing
and/or sensing type 2-triggering extrinsic stimuli are many and diverse. In
common, most of the extrinsic factors promoting type 2 immunity, as well as
the intrinsic factors sensing them, are founded on a breach of the protective
barrier of the body and thus on tissue and cellular damage.
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non-infectious environmental factors such as venoms, chemical
irritants, and xenobiotics (58). Accordingly, there may be multi-
ple pathways that lead to type 2 immunity and IgE – some more
classically “adaptive” and some more “innate” (59). The route to
type 2 immunity and whether protection or allergic sensitiza-
tion is the outcome may depend on tissue context, allergen, dose,
genetics, and species. Common for all type 2 immune responses
is that their effector functions converge at the epithelial surfaces
(skin and mucosa), vasculature, and smooth muscles where they
promote barrier defenses and expulsion. Conspicuously, aller-
gic disorders, unlike other immune pathologies, exclusively affect
epithelial tissues that interface with the environment.
Type 2 immunity can be triggered by a bewildering array
of molecules from both infectious and non-infectious sources
(Figure 1). Much work has been done to try and identify a uni-
fying framework for what makes a substance “an allergen” (60),
but common allergens such as peanut, shellfish, pollen, nickel,
bee venom, latex, house dust mite, and penicillin appear to have
little in common in terms of their chemical structure or origin.
In addition, type 2 immunity can be triggered by certain vac-
cine adjuvants [alum most notably (61)], noxious toxins (56, 58),
environmental irritants and chemicals (62, 63), as well as certain
infections or bacterial products (64). One commonality between
both infectious and non-infectious triggers of type 2 immunity
that may have been less well appreciated is that many are insults
inducing some level of physical trauma that breaches the protec-
tive barrier of the body. Tissue damage, at least in the absence
of strong type 1-promoting pathogen-associated molecular pat-
tern (PAMP) signaling, appears to be a potent mechanism driving
type 2 immunity. Tissue damage induces rapid release of several
epithelium-derived cytokine alarmins, such as IL-33, TSLP, and
IL-25 (reviewed above) – all of which can drive downstream type
2 immunity. In a macroparasite infection, the large size of the par-
asite and the consequent tissue damage it causes during invasion
may be the most important factor in inducing type 2 immunity
(65), although some parasite-derived products with direct type 2
polarizing capacity may also exist (66). The tissue-damage caused
by macroparasites may be modeled by ingestion of large inert par-
ticle structures. Interestingly, it has been shown that inert silica and
titanium particles induce innate type 2 immunity and can be used
as adjuvants promoting Th2 responses by pathways independent
of TLR4 and MyD88 (67, 68). These particles may induce cellular
damage and consequently activate endogenous danger- or stress-
signals. That“injury”or cellular stress alone can support induction
of type 2 immunity is strongly supported by results showing that
transgenic up-regulation of the NKG2D stress-ligand Rae-1 on
ECs promote potent type 2 immunity and IgE to innocuous anti-
gens (53). This rapid innate-like IgE response is also independent
of MyD88 (53). Cellular damage may also explain the type 2-
inducing effect of the adjuvant alum as injection of alum causes
the release of DAMPs, like uric acid and host cell DNA (61, 69).
Uric acid has been shown to drive type 2 immunity and again this is
via pathways independent of both MyD88 and the inflammasome
(69). Host DNA signaling intriguingly appears to differentially
regulate IgG1 and IgE production following alum-adjuvanted
immunization, where host DNA induces primary B cell responses
with IgG1 through interferon response factor 3 (Irf3)-independent
mechanism but more canonical Th2 responses and IgE through an
Irf3-dependent mechanism (70). Furthermore, extracellular ATP,
presumably released from damaged cells, binds to P2 purinergic
receptors and triggers IL-33 release and innate type 2 immune
responses in the lung (71). Oxidative stress, which is widespread
and entwined with pathological processes, has also been shown to
be involved in orchestrating type 2 immunity. For example, induc-
tion of reactive oxygen species (ROS) in ECs induces oxidation of
lipids that in turn triggers TSLP release by ECs (72) and oxida-
tive stress has been shown to induce reactive carbonyl adduction,
which is reported to be a potent driver of type 2 immunity (73).
DAMPs thus appear to be part of both the initiation and amplifi-
cation of type 2 immunity and may as such also play an important
role in allergic diseases.
Another feature that contributes to the induction of type 2
immunity by some allergens is their serine or cysteine protease
activity. Allergens such as Der P1 (from house dust mite) and
papain (from papaya fruit) appear to rely on their protolytic func-
tion as inactive forms of these proteins do not induce type 2
immunity (60). A cysteine protease from the parasite Leishmania
Mexicana has also been shown to induce type 2 immunity and this
could be blocked by protease inhibitors (66). The importance of
controlling enzymatic activity at epithelial surfaces is dramatically
demonstrated in patients with Netherton syndrome. Netherton
syndrome, which is caused by hereditary mutations in the serine
protease inhibitor, LEKTI, presents with severe disruption in bar-
rier function and persistent atopy, allergic disease, and AD (74,
75). The mutation in LEKTI results in persistent activation of
protease-activated receptor (PAR)-2 and induction of TSLP and
type 2 immunity (76).
Other endogenous stress-signals, for example the NLR recep-
tors, NOD-1, and NOD-2, can polarize antigen-specific immune
responses toward Th2 and thus contribute to the onset of adaptive
immunity (77, 78). Interestingly, NOD-1 and NOD-2 expression
within the stromal compartment is necessary to prime effector
CD4+ Th2 responses and full Th2 induction is dependent on stro-
mal TSLP (79). The type 2-inducing innate immune sensing is in
these cases recognition of bacterial-derived products (peptidogly-
cans) and not self- or environmental antigens. Although the role
of PAMPs and PRRs such as TLRs are usually associated with type
1 immunity, there are other examples in which TLR stimuli can
induce type 2 responses. For example, low doses of lipopolysac-
charides (LPS) have been proposed to promote Th2 cell responses
(whereas high doses promote Th1) (80) for which stromal expres-
sion of TLR4 is critical (81). Certain microbial stimuli that signal
via DC-SIGN induce Th2 biased responses and many TLR2 ago-
nists have also been shown to suppress Th1 and promote Th2
responses (82). Furthermore, in the case of allergens, there is evi-
dence that some can be directly sensed by PRRs; house dust mite
allergens (83) as well as nickel (84) can signal via TLR4 for instance.
Given the vast array of molecules that can trigger type 2 immu-
nity and the many innate and adaptive immune cells involved in
orchestrating the response it seems reasonable that there are sev-
eral routes to inducing type 2 responses and that these may yield a
qualitatively different kind of type 2 immunity. The conventional
mode of inducing type 2 immunity and high affinity antigen-
specific IgG1 and IgE antibody has since long been described and
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substantiated. Activated CD4+ αβ Th cells upregulate CD40L and
secrete IL-4 and IL-13, whereby they promote germ-line transcrip-
tion of the γ1 and ε heavy chain to initialize class switching. This
requires cognate interactions between B cell MHC II molecules
and the TCR–CD3 complex. However, perhaps especially with
regards to IgE, there appears to be additional non-conventional
modes of inducing class switching and the requirement for T cell
help may differ. In contrast to orthodox belief, mice that are defi-
cient in αβ T cells have highly elevated levels of IgE antibodies
and class switch particularly efficient to IgG1 and IgE (85, 86).
Mice lacking the linker for activation of T cells (LAT) adapter
protein (87) or the Tec kinase ltk also have elevated levels of
IgE (88, 89), which may be regulated non-conventionally by γδ
T cells. Evidence for a non-conventional route to IgE has also been
demonstrated during the γδ T cell dependent “lymphoid stress-
surveillance response” in the context of stressed skin epithelium
(53). It has been established that the IgE produced in immunod-
eficient mice differ from conventional adaptive IgE not only by
being MHC II-mediated T cell cognate independent but also by
lacking dependence on germinal centers and thus producing IgE
without significant somatic hypermutations (90). Moreover, this
“natural”IgE also appears to be mainly self-reactive (85, 90). It may
be that in a given circumstance a mixture of conventional adap-
tive routes and less-adaptive non-conventional routes to IgE are
operating simultaneously. For example, infection with a helminth
produces not only high affinity antigen-specific IgE but also a lot
of “non-specific” IgE and similarly NKG2D-dependent induction
of IgE from stressed skin produces not only antigen-specific IgE to
an antigen encountered simultaneously but also“non-specific”IgE
(53). Analysis of IgE repertoires and the particular requirements
for development of IgE-secreting B cells is needed to further eluci-
date conventional (via Th2) and non-conventional routes to IgE.
This may also provide invaluable information as to what actually
constitutes a host-protective response (against tissue stress, toxins,
parasites) versus allergic Th2 immunity.
IMMUNE SURVEILLANCE
To address the role of EC-driven type 2 immunity in tissue immune
surveillance it is useful to first define “immune surveillance.”
Immune surveillance refers to the capacity of the immune sys-
tem to sense cellular dysregulation and respond by activating
a stress response to restore homeostasis. This continued “qual-
ity control” mechanism has most commonly been applied to
and studied in relation to cancer. The cancer immuosurveillance
hypothesis was first proposed by Ehrlich in 1909 when he predicted
that the immune system could repress or destroy the outgrowth
of tumors that arise spontaneously on a continued basis (91).
This proposal initiated a century of debate over the immune sys-
tems role in controlling neoplasia. The idea of a natural immune
response against neoplasms or pre-malignant and dysregulated
cells was revisited and expanded by Burnet and Thomas in the
1950s (92, 93). They proposed that lymphocytes form the basis
of a “cancer immunosurveillance” process that protects immuno-
competent hosts against primary tumor development. Although
the hypothesis grew in recognition with the expansion of knowl-
edge about the immune system and tumor-antigen recognition,
the architects themselves pointed to “the problem with the idea of
immunosurveillance is that it cannot be shown to exist in experi-
mental animals” (94) – and it is of course rarely appreciated in a
clinical setting. By the early 1990s, little attention was paid to the
idea that natural immunity could control tumor establishment
de novo. However, by the mid-1990s and onward several obser-
vations were made that rekindled the interest in this early aspect
of tumor immunity [reviewed in Ref. (95)]. In short, the phys-
iological importance of immune surveillance was well revealed
by the pathological consequences of its failure: the neutralization
of IFNγ with antibodies (96) and later the use of mice lacking
IFNγ responsiveness was shown to enhance tumor growth (97).
Lymphocytes were unequivocally proven to play an essential role
in immune surveillance by seminal observations in rag2−/− mice
(98) and subsets of lymphocytes such as NK, NKT cells (99), and
γδT cells (100) were shown to play prominent roles in the con-
trol of malignancy. These new data prompted a refinement of the
cancer immunosurveillance concept (95) and an ongoing quest to
understand the triggers and mechanistic action of this early and
continuous immune response against altered self.
ELICITORS AND EFFECTORS OF IMMUNE SURVEILLANCE
Epithelial-derived cancers, called carcinomas, make up about 85%
of all cancers. The epithelial barriers of our body surfaces are
also where the majority of exogenous stresses and challenges
occur. Both sterile and microbial insults are encountered daily at
epithelial surfaces and prompt EC and immune activation. Cancer
development is, however, a multifactorial and multistep process.
Most solid cancers only emerge following a sequential accumula-
tion of somatic mutations over many years, which eventually may
overwhelm the barriers that normally restrain their growth and
thus clonal expansion of transformed cells can occur. Cumulative
mutational load, telomere dysfunction, and altered stromal milieu
are all required before a solid tumor presents (101). Fortunately,
numerous intrinsic and extrinsic tumor-supressor mechanisms
exist to prevent the development and outgrowth of malignant
cells and all cells continuously undergo these rigorous “health
checks.” The normal health control mechanisms can be triggered
both by endogenous and exogenous stress and are executed by
a cell-autonomous intrinsic surveillance system (such as delay in
cell-cycle progression, repair of DNA-damage/genetic mutations,
and induction of senescence or apoptosis) – and backed up by
extrinsic immune surveillance mechanisms triggered by manifes-
tations of EC dysregulation. The cell intrinsic responses to stress
and the cell-extrinsic responses of the immune system are therefore
intimately linked.
Damage-associated molecular patterns are mainly intracellular
components of cells that are released or exposed upon physical or
metabolic stress or cell death (102). For example ATP released from
dying cells can act as a chemoattractant on macrophages drawing
them to the stressed tissue (103). Extracellular ATP can bind to
P2 purinergic receptors, which dependent on the cell engaged, can
induce inflammatory (104) or anti-inflammatory (71) immune
responses. Release of ROS or DNA from damaged cells can also
powerfully initiate immune surveillance responses (105). Upon
stress, ECs also rapidly and potently increase their synthesis of
complement C3 (106), which due to its action on a multitude of
innate and adaptive immune cells is likely to play a role in early
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immune surveillance, although its role in cancer as well as tissue
homeostasis is as yet relatively unexplored.
In addition to the release of DAMPs, complement and
cytokines/chemokines ECs can in response to numerous forms of
cell-dysregulation dynamically alter cell-surface antigens to engage
with receptors on innate and adaptive immune cells. Ligand–
receptor interactions between ECs and tissue-resident immuno-
cytes are thus important not only for homestatic interactions but
are key regulators and elicitors of immune surveillance. One of the
most important and best-characterized families of stress-induced
EC ligands includes Rae-1, H60, and MULT1 (mouse), MICA,
MICB and ULBPs (human). These are members of the larger fam-
ily of MHC class Ib molecules and are reported upregulated on
ECs by stresses such as heat-shock, UV-irradiation, DNA-damage,
viral and bacterial infection, and autoimmunity. These unconven-
tional MHC molecules engage the activating lectin-type receptor
NKG2D, which is constitutively expressed by tissue-resident T cells
and NK, NKT cells but is also expressed on CD8+ T cells and
in some circumstances subsets of CD4+ T cells. The NKG2D-
pathway has proven important in numerous settings of cell-
dysregulation, such as cancer (107), infection (108), autoimmunity
(109), and transplantation [reviewed in Ref. (110)], and its key
role in immune surveillance is supported by the plethora of strate-
gies tumors and viruses have adopted to evade it (111, 112). In
relation to cancer, NKG2D-ligands are expressed by most epithe-
lial tumors and the NKG2D-pathway is strongly associated with
anti-tumor responses in both humans and mice (113). NKG2D-
ligands are often upregulated early upon cellular dysregulation
or transformation, it has however been controversial whether
immune cells could be activated by such self-moieties alone. By
generating transgenic mice where an autologous NKG2D-ligand,
Rae-1, could be upregulated on keratinocytes by administra-
tion of doxycycline it was shown that even in the absence of
any overt microbial stress (or overt tissue/cellular dysregulation
as in a tumor setting) engagement of NKG2D on the epider-
mal IELs (DETCs) activated these cells and caused profound
changes in the local immune compartment (114). This demon-
strates that resident immunocytes can recognize and act solely
on alterations in autologous stress antigens and thus survey the
“health-status” of a given EC, pre-malignancy. The data support
the cancer immune surveillance theory as it was also shown that
the tissue-resident IELs have a key role in host-protection against
skin carcinogenesis (114). Afferent sensing is normally attrib-
uted to innate myeloid cells, perhaps particularly to DCs that are
often viewed as the primary orchestrator of adaptive immunity.
To highlight the capacity of tissue-resident T cells (as demon-
strated by the epidermal γδT cells discussed above) to perform an
equivalent function as sensors of dysregulation, this mode of affer-
ent sensing has been termed “lymphoid stress-surveillance” (115,
116). Lymphoid stress-surveillance may particularly be engaged
in recognition of “stressed-self” and as such confer “beneficial
autoimmune” responses in our body surface tissues. It is intrigu-
ing that NKG2D is expressed primarily, perhaps exclusively, by
lymphoid cells (γδT, NKT, CD8+ αβT, and NK cells), suggest-
ing that engagement of NKG2D could elicit an acute lymphocyte
stress response to EC damage perhaps engaging different cells in
different tissues.
In addition to the NKG2D-pathway, many other ligand–
receptor pathways modulating epithelial-immune cell interactions
and contributing to immune surveillance and tissue homeostasis
are emerging. One such emerging family of regulators is the nectin
and nectin-like (necl) proteins. Nectins are immunoglobulin-like
cell–cell adhesion molecules involved in the formation of adherens
junctions in ECs and fibroblast. Both nectin and the necl molecules
play important roles not only in adhesion but also in migration,
proliferation, and wound healing (117, 118). The group of recep-
tors that engage these nectin molecules are therefore now being
intensely studied in relation to cancer and immune surveillance
(119). The major receptors that bind nectin and necl family mem-
bers are DNAM-1 (CD226, PTA-1, TLiSA1), class I-restricted T
cell-associated molecule (CRTAM), CD96, and TIGIT (WUCAM,
VSIG9, Vstm3). All of these receptors are expressed on NK cells,
γδT cells and CD8+ αβT cells and can mediate effector functions
in these cells upon engagement. DNAM-1 ligands are frequently
upregulated on tumor cells and have been reported to be regulated
through the DNA-damage response pathway (120). Activation of
DNAM-1 can evoke potent cytotoxicity in both T cells and NK
cells (121) and control tumor growth (122). CRTAM binds necl2,
which have been shown to regulate wound healing in the skin (118)
and be involved in metastasis of human tumors (123). Expression
and activation of CRTAM on immunocytes is likely highly impor-
tant in early control of tissue homeostasis and cancer immune
surveillance. In vitro studies have shown CRTAM to induce IFNγ
from T cells and in vivo ncl2 expressing tumors have been shown
to be controlled by NK and CD8+ T cells. Less is currently known
about CD96 and TIGIT, but interestingly TIGIT appears to have
an inhibitory function on NK and T cells (119).
Another example of an immune surveillance stimulator dis-
played by stressed ECs is the Coxsackie and adenovirus receptor
(CAR). CAR is also a junctional adhesion molecule, it is upreg-
ulated on damaged ECs and potentially revealed when integrity
of the tight junction is compromised. It binds junction adhe-
sion molecule-like (JAML), which is expressed on neutrophils,
tissue-resident γδT cells, and to a lesser extent on monocytes
and some activated CD8+ αβT cells. Resident skin and intesti-
nal γδT cells upregulate their expression of JAML upon tissue
injury and binding of JAML to CAR lead to proliferation, cytokine,
and growth factor production (124). Inhibiting costimulation of
resident γδT cells by blocking JAML significantly delayed wound
healing, akin to the total absence of these resident T cells, suggest-
ing that CAR-JAML interactions are important for initiation of
immune surveillance and tissue homeostasis. Interestingly, it has
been shown that interaction of JAML with CAR recruits the central
cell signal transducer PI3K, as is known for the αβT cell costimu-
lator CD28, further emphasizing JAMLs role as a costimulator for
tissue-resident T cells with implications for immune surveillance
of dysregulated ECs (125).
Similar to the role of CAR-JAML interactions between ECs
and resident T cells, it has recently been shown that plexin-B2-
CD100 interactions are important for regulating the activity of
IELs in both the skin and intestine (126, 127). CD100 (also know
as Sema4D) is a member of the large family of semaphorin pro-
teins. These proteins interact with plexins, which were first shown
to play a fundamental role in the nervous system directing axon
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guidance. Intriguingly though, semaphorin–plexin interactions
are also extensively involved in regulating immune responses and
analysis of CD100-deficient animals have revealed a crucial role for
this semaphorin in both humoral and cellular immunity (128). In
relation to EC-immunocyte interactions, plexin-B2 is expressed
on ECs in the epidermis and in the colon and interaction with
CD100 on resident γδ IELs promotes wound repair in the skin
(126) and protects against dextran sulfate sodium (DSS)-induced
colitis in the intestine (127). In both tissues, CD100−/−mice failed
to mount a proliferative EC response to tissue damage, which was
attributable to the lack of activation and growth factor production
by the γδ IELs required to heal the epithelium.
Tissue-resident immunocytes are in a unique position to carry
out a continued maintenance function such as tissue stress-
surveillance. Innate immune cells have the capacity to recognize
antigens that are displayed in tissues following a variety of stressors
and can respond rapidly in large numbers without requiring clonal
expansion. The early stages of an immune response – the afferent
phase – are therefore conventionally ascribed to myeloid cells or
NK cells. However, as highlighted above tissue-resident T cells can
also be afferent sensors of cellular dysregulation. The importance
of a tissue-specific resident population in cancer immune surveil-
lance has nevertheless been difficult to verify. This was addressed
experimentally by taking advantage of the unique tissue location
of specific γδTCR-expressing IELs in the mouse, where the epi-
dermal population of Vγ5Vδ1+ IELs can be specifically knocked
out (leaving all other T cell populations intact). These vg5vd1−/−
mice are significantly more susceptible to cutaneous carcinogen-
esis than wild-type mice, demonstrating a key role for resident
tissue-specific IELs in cancer immune surveillance. Consistent
with the cancer immune surveillance hypothesis the γδ IEL act
early and significantly suppress the development of papillomas
but cannot suppress the progression from papilloma to carcinoma
(114). Thus, myeloid cells, NK cells, and IELs all act as afferent
sensors of dysregulation and initiators of immune surveillance in
epithelial tissues. These cells can then also contribute to the down-
stream effector and regulatory phases of immunity. Clearly, both
CD4+ and CD8+ αβT cells as well as B cells play important roles
in cancer immune surveillance in the effector phase.
FUNCTIONS AND MECHANISMS OF IMMUNE
SURVEILLANCE
The afferent phase of immune surveillance – the sensing of dysreg-
ulated self – applies to many other stresses than purely oncogenic
stress. Thus the concept of immune surveillance not only per-
tains to cancer; accumulating evidence suggests that it can be
more broadly applied to other non-malignant pathologies. For
example, liver fibrosis, as a result of liver damage, is exacerbated
when NK or NKT cells are depleted or the gene for perforin
(required for cytotoxicity) is deleted as the stressed hepatic stel-
lar cells cannot be controlled (129, 130). Stressed hepatic stellar
cells express NKG2D-ligands upon damage, as described for ECs,
facilitating their recognition by immune surveillance cells. Inter-
estingly, natural activation of hepatic iNKT cells inhibits fibrosis
whereas non-natural “over-stimulation” of iNKT cells appears to
have the opposite effect and accelerate liver injury (129). Equally
in the liver, tissue-resident macrophages have been shown to
protect against ischemia reperfusion injury and be critical for
tissue homeostasis (131).
Mice lacking normal resident IEL repertoires, such as Tcrd−/−
mice, develop spontaneous chronic dermatitis, which can only
be downregulated when Tcrd−/− mice are reconstituted with the
tissue-specific resident IEL (the Vγ5Vδ1 TCR-expressing epider-
mal DETC) (132). Interestingly, these Tcrd−/− mice also show
a defect in the integrity of the epidermal barrier, as measured by
hydration status and transepidermal water loss (TEWL). However,
the epidermal barrier defect is obvious only upon environmen-
tal challenge, consistent with the notion that the IELs survey the
health-status of the ECs and promote tissue homeostasis (133).
Skin IELs were also the first T cells to be implicated in promoting
EC growth. Closure of full-thickness skin wounds is significantly
delayed in Tcrd−/− mice, and this is attributed to the skin IELs
capacity to rapidly produce EC growth factors such as insulin-like
growth factor-1 (IGF-1) and keratinocyte growth factors (KGF)
(134, 135). Intriguingly, it has also been shown in humans that T
cells isolated from healthy or acutely wounded skin actively pro-
duce EC growth factors and participate in wound repair, whereas
T cells from patients with chronic wound-healing problems are
anergic and unable to produce EC growth factors (136). Similarly,
Tcrd−/− mice lacking the γδ IEL population, which represents a
major intestinal T cell population, are more susceptible to DSS-
induced mucosal injury of the gut and demonstrate delayed tissue
repair due to the lack of localized delivery of EC growth factors
from the missing γδ IEL compartment (137).
The examples above clearly demonstrate that immune surveil-
lance is not only a mechanism to control the development and
outgrowth of tumors but is also a key regulator of tissue home-
ostasis more generally [reviewed in Ref. (138)]. The implication
of immune surveillance mechanisms in the maintenance and re-
establishment of tissue homeostasis thus broadens its scope and
it is likely that similar cell-extrinsic immune surveillance mech-
anisms are important at disease-initiating (pre-disease) stages in
many pathophysiological settings other than cancer.
Immune surveillance can function by many (non-exclusive)
mechanisms (Figure 2): (1) recognize and remove damaged,
stressed, senescent, and (pre)-malignant cells, (2) remove damag-
ing substances, waste, and dead cells, (3) facilitate re-establishment
of homeostasis by repair mechanisms, (4) neutralize potential
harmful environmental substances, or (5) dampen detrimental
inflammatory reactions.
In relation to cancer immune surveillance, the main focus has
been on type 1 immunity and cytotoxic mechanisms, both of
which have overwhelming experimental support for playing a role
in extrinsic tumor suppression. In both genetic and carcinogen-
induced tumor models, cytotoxic molecules such as perforin and
TRAIL, as well as NKG2D engagement, have repeatedly been
shown to be important in tumor control. Likewise mice lacking
type 1 molecules such as IFNγ, IFNGR, IL-12, or type I IFN recep-
tors are significantly more susceptible to carcinogenesis in several
models. Mice lacking IFNγ, perforin, TRAIL, functioning FasL
or IL-12 responsiveness can also develop spontaneous tumors of
variable origin [extensively reviewed in Ref. (139)].
However, the repair functions of immune surveillance are
clearly also very important in the early phases of immune
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FIGURE 2 | Immune surveillance with type 2 immunity promotes
tissue homeostasis and protects against carcinogenesis using
numerous layers of control. Scheme illustrating possible mechanisms
whereby tissue-resident IELs can provide rapid host-protective immune
surveillance and re-establish tissue homeostasis at body surfaces. Tissue
stress as imposed by mechanical disruption, injury, or exposure to noxious
environmental substances such as chemicals, carcinogens, UV-irradiation or
toxins prompts ECs to release IL-25, IL-33, and TSLP cytokines, and
upregulate expression of stress-ligands such as Rae-1, CAR, and plexins.
This activates the resident IELs and their responses include cytolytic
effects, release of growth factors (for example IGF-1, KGF), dampening of
αβT cell-mediated inflammation [for example by release of thymosin-β4
lymphoid splice variant (LTβ4)], rapid and potent production of IL-13, as well
as promoting humoral IgE responses. Stress surveillance by IELs can thus
recognize and remove damaged and possibly (pre-)malignant cells, promote
tissue repair, and induce type 2 immunity, which in turn controls
inflammation, expels or inactivates noxious substances, and promotes
morphological tissue homeostasis.
surveillance. This is illustrated by the link between wounding and
tumor development. It has been observed that tumors can develop
at the site of chronic skin wounds or untreated mouth ulcers (140)
and there are several case reports of lung metastasis at sites of acci-
dental trauma (141). A clear illustration of the link between a
defective wound-healing response and the development of cancer
comes from patients with epidermolysis bullosa. These patients
have mutations in genes encoding skin extracellular matrix com-
ponents and suffer from chronic skin blistering and sores – and as a
result of the chronic tissue damage are at increased risk of develop-
ing squamous cell carcinoma (142, 143). A diminished capacity to
repair a damaged barrier can thus predispose to the development
of cancer. Such associations between chronic damage/wounds and
cancer as well as the histological similarities of wounds and tumors
led to the often-cited phrase that “tumors are wounds that do not
heal” (144).
The association between chronic wounds and development
of cancer may of course not only pertain to the lack of repair
per se but also to the onset of a detrimental chronic inflam-
mation as a consequence. There is a close association between
chronic inflammation and cancer, and once a malignant cell has
escaped the early phase of immune surveillance, inflammation
can exert prominent pro-carcinogenic effects (145). The tumor-
promoting effects of inflammation are being intensively studied
and are starting to have implications for the treatment of cancers
(145, 146). An important feature of early tumor immune surveil-
lance could thus be the release of anti-inflammatory products in
the tissue. Stressed ECs promptly release many anti-inflammatory
products such as IL-33, TSLP, and IL-25 – all with the propensity
to drive anti-inflammatory type 2 immune responses. The role
of such anti-inflammatory DAMPs and type 2 immunity in early
cancer immune surveillance remains to be clarified but intrigu-
ingly when tumor-protective skin-resident IELs are activated by
stressed ECs they promptly release high levels of IL-13 (53) (and
Strid-J unpublished data). Interestingly, this IL-13 and a follow-
ing production of IgE is dependent on engagement of NKG2D
on the IELs (53), perhaps suggesting that the tumor-suppressive
effect of NKG2D and skin-resident IELs may not solely be via
cytotoxic/type 1-mediated immune surveillance mechanisms. The
surprising association between NKG2D and anti-inflammatory
type 2 immune responses (and IgE) was recently corroborated in
a model of allergic pulmonary inflammation, where mice lacking
NKG2D were resistant to the induction of allergic inflammation
and showed reduced Th2 and IgE responses (147). The association
between a stress-sensor such as NKG2D, which has been intimately
linked to anti-tumor responses, and induction of type 2 immunity
demands a closer look at the role of early type 2 immunity in can-
cer immune surveillance. The possible role of such early type 2
responses in tissue homeostasis and immune surveillance of can-
cer as well as its possible pro- and anti-tumor growth functions
are discussed in more detail below.
ROLE OF TYPE 2 IMMUNITY IN TISSUE HOMEOSTASIS AND
IMMUNE SURVEILLANCE
What is known so far of the physiological role of type 2 responses
is that their host-protection properties converge in different forms
of barrier defenses (58). This seems logical as epithelial surfaces
have a propensity to drive type 2 immunity (rather than type 1)
upon non-invasive/non-penetrating challenge or stress and type
2 immune mediators are thus well poised to play a role in early
immune surveillance as well as homeostatic tissue regulation. IL-
13 is the best-characterized inducer of mucus production and gob-
let cell hyperplasia in the respiratory and intestinal mucosa. In the
skin, transgenic over-expression of IL-13 induces skin remodeling,
which is primarily driven by TSLP (148). In both circumstances,
hyperplasia results in improved resistance to damage and damag-
ing substances at the body barrier either via production of mucus
at the mucosal surfaces or thickening of the skin. IL-13 may also
be involved in homeostatic EC differentiation/proliferation in the
skin. Epidermal IELs, which are non-redundant for normal tissue
homeostasis and wound-healing, are rapid and potent producers
of IL-13 following skin challenge (UV-radiation, tape-stripping,
NKG2D-ligand expression, and exposure to carcinogen) and mice
deficient in IL-13 have delayed barrier repair following epidermal
tape-stripping as measured by TEWL (Strid-J unpublished).
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Removal or expulsion is another host defense strategy induced
by type 2 immunity,which can directly protect against noxious tox-
ins or parasites, as well as limiting their systemic dissemination.
The removal/expulsive actions of allergic and type 2 immunity
through sneezing/coughing/itching/vomiting/diarrhea are partly
induced by EC-derived mediators including TSLP, which acts
directly on sensory neurons in the skin triggering itching (149),
and by the effect of mast cell-derived histamine on smooth mus-
cles. Type 2 immune mediators can also confer host-protection
by inactivation, neutralization, and destruction of noxious sub-
stances. This is most notably shown by the requirement for mast
cells in the detoxification of snake and bee venom (150) and
the evidence that mast cell proteases can specifically attack snake
venom at the structures required for toxicity and thereby neutral-
izing it (151). Recent data strongly suggest that IgE mediates or
at least contributes to protection against venoms as for example
the protective responses against re-challenge with high doses of
bee venom is abrogated in mice lacking B cells, FcεRI, or IgE
(56, 57). It is likely that this protection is partly via the very
rapid IgE-mediated degranulation of mast cells. Encapsulation
and restriction is another layer of barrier defense regulated by
type 2 mediators, which can help prevent the spread of nox-
ious substances if elimination or expulsion has been insufficient.
Endothelial leakage and exudate formation can be induced by mast
cell-derived products and such local tissue edema may impede
parasite invasion. For example it has been shown that the edema
caused by IgE-mediated mast cell degranulation is important in
the defense against macroparasites such as ticks (152). Another
restriction mechanism, which may restrict the spread of nox-
ious substance as well as macroparasites, involves sequestration
through granuloma formation. Type 2 immune responses protect
the host during infection with schistosomiasis by inducing granu-
lomas that sequester the tissue-damaging toxins from the parasite
eggs (153).
Perhaps most importantly, much of type 2 immunity seems
dedicated to tissue repair and promoting tolerance to damage.
Indeed, it has been hypothesized that type 2 immunity has evolved
to direct innate wound repair mechanisms (154). The rationale for
the induction of tissue repair as a part of type 2 immune defense
is obvious. It may also explain the extreme urgency of some type
2 responses (which is not easily explained if directed only toward
a slow replicating macroparasite), as damage control may well be
more important than pathogen control. In evolutionary terms,
it makes sense to be able to quickly expel or neutralize noxious
substances as well as rapidly repair the life-essential body bar-
rier. EC-derived cytokine alarmins and cell-ligands can activate
and direct the resident tissue cells to promote repair responses;
IELs rapidly sense stress and can produce growth factors locally in
the absence of further inflammation and tissue-resident ILCs can
amplify the type 2 response and produce amphiregulin. Indeed,
depletion of ILC2 compromises lung epithelial barrier integrity
(155) just as depletion of γδ IEL compromises skin and gut epithe-
lial integrity during homeostasis as well as delaying wound healing
(127, 133, 134). Almost all of the cells associated with type 2
immunity are also associated with the wound-healing response.
Alternatively activated macrophages produce vascular endothe-
lial growth factor (VEGF), arginase 1, and IGF-1; Eosinophils
store preformed growth factors, matrix metalloproteinases, and
lipid mediators, all of which can mediate wound healing (156).
Amphiregulin is produced by mast cells following FcεRI signaling,
potentially also linking IgE responses to wound repair (157). In
sum, the effects of type 2 immunity at our body surface tissues
play important roles in eliminating, restricting, and neutralizing
noxious environmental substances as well as repairing the damage
caused and minimizing inflammation – as such this type of immu-
nity is critical for tissue homeostasis and responses to challenges
that have breached the epithelial barrier.
In terms of early cancer immune surveillance, the role of type
2 immunity has been little explored. However, the effects of rapid
type 2 immune responses as outlined above could indeed play a
prominent role in cancer immune surveillance. It has been demon-
strated that the same tissue-resident IELs act as key components of
tumor resistance and potent inducers of type 2 immunity and IgE
antibodies (53, 114). The humoral component of this lymphoid
stress-surveillance response may limit tissue damage by target-
ing noxious foreign substances, such as toxins that may be the
root cause of the tissue dysregulation. The IgE effector response
may promote toxin expulsion and limit their systemic dissemina-
tion. Simultaneously, the cellular response can direct cytotoxicity
toward dysregulated cells as well as promoting repair of the dam-
aged tissue and dampening inflammation (Figures 2 and 3). To
limit the likelihood of cancer, it is clearly important to repair a
wound or breached barrier quickly and efficiently as is demon-
strated by the close association between chronic tissue damage and
cancer. Less efficient wound repair may lead to inefficient immune
surveillance against (pre-)malignant cells with damaged cells being
allowed to stay longer in the tissue before being replaced. Addi-
tionally, slow repair of tissue damage may lead to inflammation,
which as discussed can have potent pro-carcinogenic effects.
Although one can imagine a role for type 2 immunity and
its regenerative capacity in early cancer immune surveillance this
may indeed be a double-edged sword in further development of
cancer (Figure 3). Failure of the type 2 response to adequately
contain or eliminate the initiating substance may lead to a chronic
wound-healing response and exacerbation of inflammation. Such
continued tissue damage, repair, and regeneration may ultimately
result in fibrosis. Fibrotic tissue is a highly permissive environment
for tumor formation and it is also well established that continu-
ous wound-healing responses and tumorigenesis are two processes
that rely on similar molecular mechanisms (158). As such it is per-
haps not surprising that the literature on type 2/IgE responses and
cancer is somewhat bewildering.
ROLE OF TYPE 2 IMMUNITY AND IgE IN CANCER
Both positive and negative effects of type 2 immunity on tumor
growth and carcinogenesis have been reported in the literature
(Table 1). Contrasting results are clearly in part due to the dif-
fering experimental approaches and models but most likely also
reflects the divergent roles that type 2 immunity may play at dif-
ferent stages of carcinogenesis and in different tissues. CD4+ T
cell-derived IL-4 has been reported to induce granulocyte infiltra-
tion, thereby promoting tumor clearance (an action enhanced by
IL-13), and conversely increase tumor cells’ resistance to apop-
tosis by up-regulation of anti-apoptotic proteins (159). Many
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FIGURE 3 | Contrasting role of type 2 immunity in immune surveillance
of early tissue dysregulation versus tumor progression. The type 2
component of immune surveillance may aid in host-protection against
carcinogenesis at epithelial surfaces by removing the oncogenic insult,
eliminating the dysregulated cells, dampening excessive inflammation,
repairing tissue, re-establishing homeostasis, as well as improving resistance
to future damage. However, following continuous perturbations, failure to
eliminate the initial insult or dysregulated immune surveillance a tipping point
may be reached where excessive tissue damage and DAMPs lead to
inflammation, disproportionate cellular infiltrates, and escape from immune
surveillance and tissue homeostasis. Once a certain level of tissue damage is
reached, a perpetual type 2 response may be detrimental to the host by
transitioning to aid carcinogenesis by promoting a chronic wound-healing
response and fibrosis as well as supporting neo-angiogenesis.
studies carried out in the 1990s and early 2000s demonstrated
that tumors or tumor cell lines engineered to produce IL-4 would
exhibit increased rejection and retarded growth in vivo; curi-
ously a phenotype often dependent on CD8+ cytotoxic T cells
(160–163). IL-10 has been reported to be both “pro-tumorigenic”
by inhibiting tumor cell lysis by cytotoxic T cells and “anti-
tumorigenic” by promoting NK-cell-mediated tumor clearance
and inhibiting angiogenesis (164). The EC-derived cytokines IL-
33 and TSLP have been shown to enhance tumorigenesis by
promoting epithelial-mesenchycmal transition (EMT) in organ-
otypic culture of ex vivo carcinoma-associated fibroblasts (CAFs)
and squamous cell carcinoma cells (165) and by enhancing Th2
inflammation (166). On the contrary TSLP has convincingly been
shown in mouse in vivo models to be critically important for
resistance to skin carcinogenesis (35, 36) establishing TSLP as
a tumor suppressor in the skin. Many epithelial cancers express
receptors for type 2 mediators such as IL-4 and IL-13, allow-
ing for a direct effect on tumor growth, death, and proliferation
that is independent of their effect on immunocytes (167). This
perhaps also explains the likely divergent effects of type 2 immu-
nity in early cancer immune surveillance versus in established
tumors. Human breast and renal cancer cell lines treated with
exogenous IL-13 in vitro demonstrate reduced proliferation (168–
170) – although an ovarian cancer line demonstrated enhanced
invasive and enzyme (protease) activity (171) suggesting IL-13
aids primary tumor invasion and metastasis in this model. No
doubt the heterogeneity of cancer cell lines and ex vivo tumors
derived from patients and experimental animals clouds a consis-
tent description of how potent type 2 cytokines may affect growth
and immune surveillance of tumors in vivo. Cellular type 2 play-
ers, such as eosinophils, have an extensive description in the cancer
literature, and have been shown to play a protective role against
chemically induced tumors in vivo – and directly kill chemically
induced fibrosarcomas in vitro (172), suggesting efficacious tissue
immune surveillance. Mast cells frequently infiltrate the tumor
microenvironment and are usually correlated with a poor prog-
nosis in human cancers (173), although both tumor rejection and
promotion has been attributed to them in the mouse. Interestingly,
the ancient and highly conserved (174) immunoglobulin isotype
IgE has been shown to play a significant role in immune surveil-
lance of tumors. Since the 1990s IgE mAbs have been considered
for cancer immunotherapy; particularly given IgE’s extreme bio-
logical potency and presence of high and low affinity receptors
on various effector cell types (175). Indeed, animals deficient in
IgE show drastically altered susceptibility to cutaneous chemical
carcinogenesis, and an altered tumor cytokine microenvironment
(Dalessandri-T and Strid-J; unpublished). IgE-coated irradiated
tumor cells has also been shown to generate protective, eosinophil,
and T cell immunity to subsequently administered non-irradiated
tumors (176). In addition, the type 2 immunoglobulin IgG1 has
been reported to be potently tumoricidal when not “blocked” by
competing IgG4 antibodies (177).
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Table 1 | Examples of type 2 cytokines and immunoglobulins influencing tumor pathology.
Type 2 mediator Experimental approach Model Tumor growth
IL-4 Tumors engineered to produce IL-4,
IL-4 ↑
Primary murine renal cancer
Injection of syngeneic tumor cell lines
↓ Enhanced CD8+ T cell-dependent rejection (160)
↓ Enhanced CD8+ T cell-dependent rejection (161)
↑ Delayed primary tumor clearance, increased
secondary tumor development (178)
↑ Reduced CD8+ T cell-mediated clearance (178)
Primary murine adenocarcinoma ↓ Enhanced CD8+ T cell-dependent and
eosinophil-mediated rejection (162)
Vaccination with irradiated tumor cells ↓ Enhanced CD8+ T cell-dependent clearance of lung
metastases (163)
Exogenous rIL-4 treatment, IL-4 ↑ Prostate, breast and bladder cancer
cell lines
↑ Enhanced resistance to apoptosis and
chemotherapeutic agents (159)
IL-13 Tumors engineered to produce IL-13,
IL-13 ↑
Injection of P815 mastocytoma cell line ↓ Improved rejection and development of systemic
anti-tumor immunity (179)
Exogenous IL-13 treatment, IL-13 ↑ Ex vivo leukemic B blasts ↓ Reduced proliferation and cell-cycle progression
assessed by DNA content (168)
Human breast cancer cell line ↓ Inhibition of estrogen-induced cell proliferation,
unchanged basal proliferation (169)
Human renal carcinoma cell line ↓ Reduced proliferation and colony formation (170)
Ovarian cancer cell line ↑ Increased MMP and AP-1-dependant invasion and
protease activity in matrigel invasion assay (171)
Antibody-mediated IL-13
neutralization, IL-13 ↓
Hodgkin lymphoma cell line ↓ Decreased proliferation and STAT6 phosphorylation
(180)
IL-33 IL-33 receptor knockout (ST2−/−),
IL-33-signaling ↓
ST2−/−mammary carcinoma-bearing
mice
↓ Attenuated tumor growth and metastasis, increased
number and cytotoxic activity of NK cells (181)
Exogenous IL-33 treatment, IL-33 ↑ 4T1 cell line tumor-bearing mice ↑ Reduced intra-tumoral tumoricidal NK cells,
increased splenic MDSCs and M2 macrophages (182)
IL-33 co-admin, with HPV DNA
vaccine, IL-33 ↑
TC-1 cell line (HPV-16 E7-positive)
tumor-bearing mice
↓ Improved HPV antigen-specific CD4 and CD8 T
cells, increased TC-1 regression (183)
Organotypic culture, IL-33 ↑ Ex vivo human carcinoma-
associated fibroblasts (CAFs)
↑ CAFs promote carcinoma invasion via IL-33 signaling
and EMT induction (165)
TSLP Antibody-mediated TSLP
neutralization, TSLP ↓
Murine breast tumor xenograft ↓ Inhibition of tumor development (166)
K14-TSLPTgor calcipotriol induced
TSLP, TSLP ↑
DMBA/TPA chemical skin
carcinogenesis
↓ Delayed tumor onset and significantly reduced
tumor number and growth (35)
TSLP receptor knockout or TSLP
neutralization, TSLP-signaling ↓
Notchl/Notch2 receptor knockout ↑ Loss of TSLP-signaling in Notch-deficient epidermis
leads to tumor formation (36)
IgE IgE-loaded tumor cell vaccine, IgE ↑ Post-vaccination challenge with RMA
lymphoma or MC38 adenocarcinoma
↓ Improved protective eosinophil, CD4+ and CD8+ T
cell responses to tumor challenge (176, 184)
IgGl Engineered tumor-antigen-specific
IgG4, IgGl ↓
Human melanoma xenograft model ↑ IgG4 blocked potent IgGl-mediated anti-tumor
effector functions (177)
EPIDEMIOLOGICAL AND CLINICAL ASSOCIATIONS
BETWEEN TYPE 2 IMMUNITY, IgE AND CANCER
Associations between allergy history and cancer risk have been
investigated in numerous epidemiological studies and their asso-
ciation is being defined in the nascent field of “AllergoOncology”
(Table 2). Recent overviews of the epidemiological literature
demonstrate that both potent inverse and positive associations
exist, which point to complex underlying interactions as well
as reflecting the heterogeneity of these diseases. Accordingly,
although the relationship between cancer and allergy has intrigued
researchers for decades, the biological nature of this association
remains unclear.
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Table 2 | Proposed hypotheses explaining associations between type 2 immunity/allergy and cancer.
Hypothesis Predicted allergy–
cancer relationship
Predicted affected
tissue site
Proposed mechanisms
Antigenic stimulation or chronic
inflammation (185)
Positive, causal All sites • Allergic inflammation and oxidative damage promote pro-tumorigenic
gene mutations
• Type 2-induced tissue remodeling and angiogenesis promotes tumor
growth and invasion
InappropriateTh2 skewing (186) Positive, causal All sites • Diversion away from protective cytolytic type 1 responses
• Non-protective IgE clonality, or poorly tumoricidal IgG4 class switching
with immunosuppressive IL-10
Immune surveillance (93) Inverse, causal All sites • Potent effector cells, including γδT cells, mast cells and eosinophils
eradicate tumors
• Tumor-specific IgE potently cytolytic via ADCC
• Type 2 immunity repairs tissue damage and dampens inflammation
hereby restricting tumor formation
Prophylaxis (55) Inverse, causal Mucosal and
external surfaces
• Tissue type 2 immunity removes or neutralizes noxious and potentially
carcinogenic environmental moieties before they cause genotoxicity
• Type 2 immunity restricts systemic dissemination of noxious
substances and enhances natural barrier defenses
Two hypotheses put forward to explain positive allergy–cancer
associations are the “antigenic stimulation”/“chronic inflamma-
tion” hypothesis and the “inappropriate Th2 skewing” hypothesis
(Table 2). The “antigenic stimulation” hypothesis was first pro-
posed in the late 1980s (185) and has been reiterated numerous
times, also termed the “chronic inflammation” hypothesis (186).
This hypothesis proposes that inflammation associated with aller-
gic disease establishes a tissue environment conducive to tumor
growth. Indeed, more than 100 years ago a link between inflam-
mation and cancer was first proposed by Virchow (146), who noted
the presence of leukocytes in neoplastic tissues and suggested can-
cer originated at sites of chronic inflammation. Tissue damage
with the release of DAMPs, chronic infection, and inflammation
are all believed to contribute to the development of malignant dis-
ease. Mechanistically, cellular Th2-mediators such as macrophages
promote oxidative damage through production of iNOS and
hydrogen peroxide via the respiratory burst, increasing the like-
lihood of damage and mutation of tumor-suppressor genes or
cell-cycle regulator genes. Tissue remodeling and pro-angiogenesis
factors such as vasoactive mediators from tissue-resident mast cells
and eosinophils, as well as VEGF, arginase and matrix metallopro-
teases released by macrophages, may promote local invasion of
outgrowing tumors, and eventual metastasis with establishment
of distal secondary loci worsening clinical outcome. Thus, the
“antigenic stimulation/chronic inflammation” hypothesis predicts
a positive relationship between allergic disease and cancer in any
tissue site and this relationship is directly causal, i.e., inflammation
secondary to or as a result of allergic disease directly promotes
oncogenesis. The “inappropriate Th2 skewing” hypothesis (186)
suggests that type 2 mediators – such as IL-4, IL-10, IL-13 –
may redirect tissue immunity away from a potently anti-tumor
and cytolytic Th1 response, toward an ineffective Th2 response,
where IgE is produced and directed toward allergens and not
tumor-specific or tumor-associated antigens. Additionally, with
production of immunomodulatory IL-10, Th2-immunogloublin
IgG4 class-switch recombination is favored over IgE, the former
being far less potently tumoricidal, further attenuating anti-tumor
responses. This hypothesis therefore also predicts a positive rela-
tionship between allergic disease and cancer, in any tissue site, and
this relationship is directly causal – skewing to type 2 responses
that are non-protective and aids oncogenesis.
Two hypotheses put forward to explain inverse allergy–cancer
associations are the “immune surveillance” hypothesis, and the
“prophylaxis” hypothesis (Table 2). Prophylaxis was first proposed
by Profet (55), and suggests that the symptoms and mechanisms
of allergic disease serve to repel and clear potentially muta-
genic substances at the external body surfaces before mutagenesis
can occur; a coopted function of type 2 immunity which also
serves to expel parasites and helminths. Itch induced by type
2 mediators such as TSLP, goblet cell hypersecretion of mucus,
sneezing, coughing, vomiting, and diarrhea all act as repulsive
mechanisms and are particularly common allergy symptoms. In
additional to physical expulsion, type 2 cellular players directly
deactivate noxious xenobiotics. In mice at least, mast cells have
been shown to degrade venom components through release of
carboxypeptidases (150), and IgE raised to a conserved compo-
nent (and allergen) of many venoms is protective against a repeat
exposure (56, 57). The unpleasantness of allergy symptoms also
conditions the animal to avoid potentially carcinogenic triggers.
Thus, the “prophylaxis” hypothesis predicts an inverse, causal rela-
tionship between allergic disease and cancer, particularly at the
exposed body barrier surfaces. This hypothesis requires that moi-
eties encountered at the body surfaces are directly carcinogenic,
or are pro-carcinogens, and predicts that individuals with allergy
symptoms should present with (i) lower levels of carcinogens in
their blood and (ii) restrictive or obstructive disease at mucosal
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surfaces – or that treatment to reduce allergic symptoms results in
greater vulnerability to cancer at those sites (187). These corollar-
ies of the “prophylaxis” hypothesis have been poorly investigated.
The “immune surveillance” hypothesis, first proposed by Bur-
net (93), also predicts an inverse allergy–cancer relationship and
inverse associations are predicted at any body site. It suggests that
allergy and atopic symptoms are indicative of an immune system
that is generally hyper-responsive to challenge, and has enhanced
immune surveillance capability. Potently cytolytic type 2 responses
raised against tumor-associated or -specific antigens can rapidly
eradicate dysregulated and proto-neoplastic cells; hence allergy
symptoms are a fortuitous, albeit unpleasant, result of an indi-
vidual’s potent immune system, which also controls dysregulated
cells and results in an inverse allergy–cancer relationship. Although
the inverse allergy–cancer relationship proposed by the “immune
surveillance” hypothesis was originally thought to be purely cor-
relational, as argued in this review, type 2 immunity is also likely
to play an important role in early immune surveillance in a direct
casual manner by virtue of its ability to remove noxious substances,
repair tissue damage and dampen initial inflammation.
In spite of many speculations and associations there is little evi-
dence for a strong association between allergy and overall cancer
risk (188). However, given that allergic disease occurs primarily at
outer epithelial surfaces it is logical to examine the incidence of
cancer at specific tissue sites, particularly those at which allergic
disease is prevalent; such as the skin, respiratory, and gastrointesti-
nal tracts. A recent large meta-analysis of more than 400 studies
of relationships between allergy and cancer reported a preponder-
ance of inverse allergy–cancer associations, and interestingly this
was particularly strong for cancers of tissues that interface with
the external environment, such as skin, mouth, throat, colon, and
cervix (187). These results support the “prophylaxis” as well as the
“immune surveillance” hypotheses. Intriguingly, while most stud-
ies investigate the link between specifically Type I allergic disease
and cancer, a significant inverse association between contact (Type
IV) hypersensitivity and breast and non-melanoma skin cancer has
been reported, and the authors suggested these data support the
“immune surveillance” hypothesis (189).
The large number of published association studies neverthe-
less often paints a conflicting picture, some of which may be
due to methodological constraints. Most retrospective studies
on allergy–cancer associations have investigated self-reported or
clinician-diagnosed allergy, methodologies particularly prone to
recollection and reporting bias (former) and subject selection bias
(latter). Researchers have attempted to alleviate these concerns at
least in part by discriminating subjects on the basis of physiological
indices of allergic disease, such as serum IgE titers (190, 191) and
skin-prick testing. Of course, serum total or allergen-specific IgE
suffers less from human biases, but these are not a definite metric
of allergic status in all individuals, all of the time; in addition this
methodology potentially precludes the possibility of examining
significant non-Type I hypersensitivities in the analysis. Another
concern is that if variation between individual’s allergy symptoms
is due more to differences in individual’s exposure to antigens
and/or carcinogens (the environment as a confounding variable),
rather than individual differences in immunity (“immune sur-
veillance” hypothesis), then positive correlations between allergic
symptoms and cancer may occur – even if the “prophylaxis” or
“immune surveillance”hypotheses are true. Particularly, given that
exposure to carcinogenic allergens (such as cigarette smoke or
vehicle exhaust) results in increased cancer and allergic disease
(187). In addition, the genetic and phenotypic heterogeneity of
tumors, and the complex inflammatory niche in which they reside,
may also confound epidemiological association studies.
CONCLUDING REMARKS
Epithelial cancers are products of a series of events starting with
dysregulated and stressed ECs. It is now clear that challenges to
ECs can trigger discrete pathways promoting the release of specific
cytokines, chemokines, and expression of stress antigens on the
EC surface. Together this can powerfully drive immune responses,
initially from cells resident in the epithelial and subepithelial com-
partment. The initial response to EC challenge and damage is often
a very rapid type 2 immune response. This may serve to remove or
neutralize noxious challenging substances, clear waste, repair the
tissue, dampen inflammation, and re-establish tissue homeostasis.
It may also directly contribute to the elimination of damaged cells
together with cytolytic mechanisms from resident IELs and other
immunocytes. Rapid type 2 immune responses at body surfaces
thus prominently contribute to immune surveillance of dysregu-
lated ECs. Since epithelial dysregulation contributes notably to a
multitude of inflammatory diseases, this may not only be impor-
tant in control of (pre-)malignancy but could be important at
disease-initiating stages in a variety of diseases.
Immune surveillance by its nature is mainly important in the
initiation phase of tissue damage and tumor control – for main-
tenance of tissue homeostasis. The same effector molecules and
mechanisms may play a very different role during the progression
phase of tissue damage and tumor growth. Failure to eliminate the
original damaging substance, damaged cells, or to repair the tissue
may lead to a continual stress response with excessive release of
DAMPs, persistent stress-ligand expression, inflammation, and a
chronic wound-healing response and this may determine the tran-
sition point between beneficial and detrimental functions of type 2
immunity in the course of disease. Similarly, continual exposure to
noxious environmental substances may eventually overwhelm the
immune surveillance mechanisms keeping the damage in check
and result in pathology or tumor growth. Further research is
needed to study whether the balance between tumor cell growth
and elimination may be tipped back upon immune manipulations
aimed at enhancing naturally occurring immune surveillance.
ACKNOWLEDGMENTS
We thank colleagues within our laboratory and beyond for insight-
ful discussions and especially Dr. Olga Sobolev for critical review
of the manuscript. Apologies to colleagues whose work has inad-
vertently been overlooked or that were a victim of space con-
straints. We thank the Wellcome Trust for funding and declare no
competing financial interests.
REFERENCES
1. Swamy M, Jamora C, Havran W, Hayday A. Epithelial decision makers: in
search of the“epimmunome.”Nat Immunol (2010) 11(8):656–65. doi:10.1038/
ni.1905
Frontiers in Immunology | Tumor Immunity July 2014 | Volume 5 | Article 347 | 14
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dalessandri and Strid Type 2 immunity regulate tissue homeostasis
2. Nestle FO, Di Meglio P, Qin J-Z, Nickoloff BJ. Skin immune sentinels in health
and disease. Nat Rev Immunol (2009) 9(10):679–91. doi:10.1038/nri2622
3. Jackson SP, Bartek J. The DNA-damage response in human biology and disease.
Nature (2009) 461(7267):1071–8. doi:10.1038/nature08467
4. Wood LC, Elias PM, Calhoun C, Tsai JC, Grunfeld C, Feingold KR. Barrier
disruption stimulates interleukin-1 alpha expression and release from a pre-
formed pool in murine epidermis. J Invest Dermatol (1996) 106(3):397–403.
doi:10.1111/1523-1747.ep12343392
5. Jerde TJ, Bushman W. IL-1 induces IGF-dependent epithelial proliferation in
prostate development and reactive hyperplasia. Sci Signal (2009) 2(86):ra49.
doi:10.1126/scisignal.2000338
6. Culig Z, Puhr M. Interleukin-6: a multifunctional targetable cytokine in human
prostate cancer. Mol Cell Endocrinol (2012) 360(1–2):52–8. doi:10.1016/j.mce.
2011.05.033
7. Fort MM, Cheung J, Yen D, Li J, Zurawski SM, Lo S, et al. IL-25 induces IL-
4, IL-5, and IL-13 and Th2-associated pathologies in vivo. Immunity (2001)
15(6):985–95. doi:10.1016/S1074-7613(01)00243-6
8. Lee J, Ho WH, Maruoka M, Corpuz RT, Baldwin DT, Foster JS, et al. IL-17E, a
novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1. J Biol
Chem (2001) 276(2):1660–4. doi:10.1074/jbc.M008289200
9. Owyang AM, Zaph C, Wilson EH, Guild KJ, McClanahan T, Miller HRP,
et al. Interleukin 25 regulates type 2 cytokine-dependent immunity and lim-
its chronic inflammation in the gastrointestinal tract. J Exp Med (2006)
203(4):843–9. doi:10.1084/jem.20051496
10. Zaph C, Du Y, Saenz SA, Nair MG, Perrigoue JG, Taylor BC, et al. Commensal-
dependent expression of IL-25 regulates the IL-23-IL-17 axis in the intestine.
J Exp Med (2008) 205(10):2191–8. doi:10.1084/jem.20080720
11. Zaiss MM, Maslowski KM, Mosconi I, Guenat N, Marsland BJ, Harris NL.
IL-1β suppresses innate IL-25 and IL-33 production and maintains helminth
chronicity. PLoS Pathog (2013) 9(8):e1003531. doi:10.1371/journal.ppat.
1003531
12. Heneghan AF, Pierre JF, Gosain A, Kudsk KA. IL-25 improves luminal innate
immunity and barrier function during parenteral nutrition. Ann Surg (2014)
259(2):394–400. doi:10.1097/SLA.0b013e318284f510
13. Angkasekwinai P, Park H, Wang Y-H, Wang Y-H, Chang SH, Corry DB, et al.
Interleukin 25 promotes the initiation of proallergic type 2 responses. J Exp
Med (2007) 204(7):1509–17. doi:10.1084/jem.20061675
14. Wang Y-H, Angkasekwinai P, Lu N, Voo KS, Arima K, Hanabuchi S, et al. IL-25
augments type 2 immune responses by enhancing the expansion and functions
of TSLP-DC-activated Th2 memory cells. J Exp Med (2007) 204(8):1837–47.
doi:10.1084/jem.20070406
15. Gregory LG, Jones CP, Walker SA, Sawant D, Gowers KHC, Campbell GA, et al.
IL-25 drives remodelling in allergic airways disease induced by house dust mite.
Thorax (2013) 68(1):82–90. doi:10.1136/thoraxjnl-2012-202003
16. Hams E, Armstrong ME, Barlow JL, Saunders SP, Schwartz C, Cooke G, et al.
IL-25 and type 2 innate lymphoid cells induce pulmonary fibrosis. Proc Natl
Acad Sci U S A (2014) 111(1):367–72. doi:10.1073/pnas.1315854111
17. Deleuran M, Hvid M, Kemp K, Christensen GB, Deleuran B, Vestergaard C.
IL-25 induces both inflammation and skin barrier dysfunction in atopic der-
matitis. Chem Immunol Allergy (2012) 96:45–9. doi:10.1159/000331871
18. Salimi M, Barlow JL, Saunders SP, Xue L, Gutowska-Owsiak D, Wang X, et al.
A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic der-
matitis. J Exp Med (2013) 210(13):2939–50. doi:10.1084/jem.20130351
19. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al.
IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related
protein ST2 and induces T helper type 2-associated cytokines. Immunity (2005)
23(5):479–90. doi:10.1016/j.immuni.2005.09.015
20. Komai-Koma M, Brombacher F, Pushparaj PN, Arendse B, McSharry C,
Alexander J, et al. Interleukin-33 amplifies IgE synthesis and triggers mast cell
degranulation via interleukin-4 in naïve mice. Allergy (2012) 67(9):1118–26.
doi:10.1111/j.1398-9995.2012.02859.x
21. Humphreys NE, Xu D, Hepworth MR, Liew FY, Grencis RK. IL-33, a potent
inducer of adaptive immunity to intestinal nematodes. J Immunol (2008)
180(4):2443–9. doi:10.4049/jimmunol.180.4.2443
22. Pastorelli L, Garg RR, Hoang SB, Spina L, Mattioli B, Scarpa M, et al. Epithelial-
derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and
in experimental Th1/Th2 driven enteritis. Proc Natl Acad Sci U S A (2010)
107(17):8017–22. doi:10.1073/pnas.0912678107
23. Fux M, Pecaric-Petkovic T, Odermatt A, Hausmann OV, Lorentz A, Bischoff
SC, et al. IL-33 is a mediator rather than a trigger of the acute allergic response
in humans. Allergy (2014) 69(2):216–22. doi:10.1111/all.12309
24. Imai Y, Yasuda K, Sakaguchi Y, Haneda T, Mizutani H, Yoshimoto T, et al. Skin-
specific expression of IL-33 activates group 2 innate lymphoid cells and elicits
atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci U S A (2013)
110(34):13921–6. doi:10.1073/pnas.1307321110
25. Hueber AJ, Alves-Filho JC, Asquith DL, Michels C, Millar NL, Reilly JH, et al.
IL-33 induces skin inflammation with mast cell and neutrophil activation. Eur
J Immunol (2011) 41(8):2229–37. doi:10.1002/eji.201041360
26. Yanaba K, Yoshizaki A, Asano Y, Kadono T, Sato S. Serum IL-33 levels are
raised in patients with systemic sclerosis: association with extent of skin scle-
rosis and severity of pulmonary fibrosis. Clin Rheumatol (2011) 30(6):825–30.
doi:10.1007/s10067-011-1686-5
27. Yin H, Li X, Hu S, Liu T,Yuan B, Gu H, et al. IL-33 accelerates cutaneous wound
healing involved in upregulation of alternatively activated macrophages. Mol
Immunol (2013) 56(4):347–53. doi:10.1016/j.molimm.2013.05.225
28. Allakhverdi Z, Comeau MR, Jessup HK, Yoon B-RP, Brewer A, Chartier S, et al.
Thymic stromal lymphopoietin is released by human epithelial cells in response
to microbes, trauma, or inflammation and potently activates mast cells. J Exp
Med (2007) 204(2):253–8. doi:10.1084/jem.20062211
29. Saenz SA, Taylor BC, Artis D. Welcome to the neighborhood: epithelial cell-
derived cytokines license innate and adaptive immune responses at mucosal
sites. Immunol Rev (2008) 226:172–90. doi:10.1111/j.1600-065X.2008.00713.x
30. Zaph C, Troy AE, Taylor BC, Berman-Booty LD, Guild KJ, Du Y, et al. Epithelial-
cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis.
Nature (2007) 446(7135):552–6. doi:10.1038/nature05590
31. Ziegler SF,Artis D. Sensing the outside world: TSLP regulates barrier immunity.
Nat Immunol (2010) 11(4):289–93. doi:10.1038/ni.1852
32. Al-Shami A, Spolski R, Kelly J, Keane-Myers A, Leonard WJ. A role for TSLP
in the development of inflammation in an asthma model. J Exp Med (2005)
202(6):829–39. doi:10.1084/jem.20050199
33. Indra AK. Epidermal TSLP: a trigger factor for pathogenesis of atopic dermati-
tis. Expert Rev Proteomics (2013) 10(4):309–11. doi:10.1586/14789450.2013.
814881
34. Yoo J, Omori M, Gyarmati D, Zhou B, Aye T, Brewer A, et al. Sponta-
neous atopic dermatitis in mice expressing an inducible thymic stromal lym-
phopoietin transgene specifically in the skin. J Exp Med (2005) 202(4):541–9.
doi:10.1084/jem.20041503
35. Demehri S, Turkoz A, Manivasagam S, Yockey LJ, Turkoz M, Kopan R. Elevated
epidermal thymic stromal lymphopoietin levels establish an antitumor envi-
ronment in the skin. Cancer Cell (2012) 22(4):494–505. doi:10.1016/j.ccr.2012.
08.017
36. Di Piazza M, Nowell CS, Koch U, Durham A-D, Radtke F. Loss of cuta-
neous TSLP-dependent immune responses skews the balance of inflammation
from tumor protective to tumor promoting. Cancer Cell (2012) 22(4):479–93.
doi:10.1016/j.ccr.2012.08.016
37. Jiang J, Hui C-C. Hedgehog signaling in development and cancer. Dev Cell
(2008) 15(6):801–12. doi:10.1016/j.devcel.2008.11.010
38. Furmanski AL, Saldana JI, Ono M, Sahni H, Paschalidis N, D’Acquisto F, et al.
Tissue-derived hedgehog proteins modulate Th differentiation and disease.
J Immunol (2013) 190(6):2641–9. doi:10.4049/jimmunol.1202541
39. Kim J, Myers AC, Chen L, Pardoll DM, Truong-Tran Q-A, Lane AP, et al. Con-
stitutive and inducible expression of b7 family of ligands by human airway
epithelial cells. Am J Respir Cell Mol Biol (2005) 33(3):280–9. doi:10.1165/
rcmb.2004-0129OC
40. Bas A, Swamy M, Abeler-Dörner L, Williams G, Pang DJ, Barbee SD, et al.
Butyrophilin-like 1 encodes an enterocyte protein that selectively regulates
functional interactions with T lymphocytes. Proc Natl Acad Sci U S A (2011)
108(11):4376–81. doi:10.1073/pnas.1010647108
41. Boyden LM, Lewis JM, Barbee SD, Bas A, Girardi M, Hayday AC, et al. Skint1,
the prototype of a newly identified immunoglobulin superfamily gene clus-
ter, positively selects epidermal γδ T cells. Nat Genet (2008) 40(5):656–62.
doi:10.1038/ng.108
42. Turchinovich G, Hayday AC. Skint-1 identifies a common molecular mech-
anism for the development of interferon-γ-secreting versus interleukin-17-
secretingγδT cells. Immunity (2011) 35(1):59–68. doi:10.1016/j.immuni.2011.
04.018
www.frontiersin.org July 2014 | Volume 5 | Article 347 | 15
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dalessandri and Strid Type 2 immunity regulate tissue homeostasis
43. Rölle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Söderberg-Nauclér C, Cosman
D, et al. Effects of human cytomegalovirus infection on ligands for the acti-
vating NKG2D receptor of NK cells: up-regulation of UL16-binding protein
(ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol
(2003) 171(2):902–8. doi:10.4049/jimmunol.171.2.902
44. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands
for the NKG2D activating receptor. Annu Rev Immunol (2013) 31(1):413–41.
doi:10.1146/annurev-immunol-032712-095951
45. Jung H, Hsiung B, Pestal K, Procyk E, Raulet DH. RAE-1 ligands for the NKG2D
receptor are regulated by E2F transcription factors, which control cell cycle
entry. J Exp Med (2012) 209(13):2409–22. doi:10.1084/jem.20120565
46. Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to
immunology. Nat Rev Immunol (2013) 13(2):88–100. doi:10.1038/nri3384
47. Cheroutre H, Lambolez F, Mucida D. The light and dark sides of intestinal
intraepithelial lymphocytes. Nat Rev Immunol (2011) 11(7):445–56. doi:10.
1038/nri3007
48. Gebhardt T, Wakim LM, Eidsmo L, Reading PC, Heath WR, Carbone FR.
Memory T cells in nonlymphoid tissue that provide enhanced local immunity
during infection with herpes simplex virus. Nat Immunol (2009) 10(5):524–30.
doi:10.1038/ni.1718
49. Jiang X, Clark RA, Liu L, Wagers AJ, Fuhlbrigge RC, Kupper TS. Skin infection
generates non-migratory memory CD8+ T(RM) cells providing global skin
immunity. Nature (2012) 483(7388):227–31. doi:10.1038/nature10851
50. Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S, et al. Th22
cells represent a distinct human T cell subset involved in epidermal immunity
and remodeling. J Clin Invest (2009) 119(12):3573–85. doi:10.1172/JCI40202
51. Cella M, Fuchs A, Vermi W, Facchetti F, Otero K, Lennerz JKM, et al. A human
natural killer cell subset provides an innate source of IL-22 for mucosal immu-
nity. Nature (2008) 457(7230):722–5. doi:10.1038/nature07537
52. Björkström NK, Kekäläinen E, Mjösberg J. Tissue-specific effector functions of
innate lymphoid cells. Immunology (2013) 139(4):416–27. doi:10.1111/imm.
12098
53. Strid J, Sobolev O, Zafirova B, Polic B, Hayday A. The intraepithelial T cell
response to NKG2D-ligands links lymphoid stress surveillance to atopy. Science
(2011) 334(6060):1293–7. doi:10.1126/science.1211250
54. Harris N, Gause WC. To B or not to B: B cells and the Th2-type immune
response to helminths. Trends Immunol (2011) 32(2):80–8. doi:10.1016/j.it.
2010.11.005
55. Profet M. The function of allergy: immunological defense against toxins. Q Rev
Biol (1991) 66(1):23–62. doi:10.1086/417049
56. Marichal T, Starkl P, Reber LL, Kalesnikoff J, Oettgen HC, Tsai M, et al. A
beneficial role for immunoglobulin in host defense against honeybee venom.
Immunity (2013) 39(5):963–75. doi:10.1016/j.immuni.2013.10.005
57. Palm NW, Rosenstein RK, Yu S, Schenten DD, Florsheim E, Medzhitov R. Bee
venom phospholipase A2 induces a primary type 2 response that is depen-
dent on the receptor ST2 and confers protective immunity. Immunity (2013)
39(5):976–85. doi:10.1016/j.immuni.2013.10.006
58. Palm NW, Rosenstein RK, Medzhitov R. Allergic host defences. Nature (2012)
484(7395):465–72. doi:10.1038/nature11047
59. Gutierrez DA, Rodewald H-R. A sting in the tale of Th2 immunity. Immunity
(2013) 39(5):803–5. doi:10.1016/j.immuni.2013.10.015
60. Traidl-Hoffmann C, Jakob T, Behrendt H. Determinants of allergenicity.
J Allergy Clin Immunol (2009) 123(3):558–66. doi:10.1016/j.jaci.2008.12.003
61. Kool M, Lambrecht BN. Alum adjuvant boosts adaptive immunity by induc-
ing uric acid and activating inflammatory dendritic cells. J Exp Med (2008)
205(4):869–82. doi:10.1084/jem.20071087
62. Fukuyama T, Tajima Y, Ueda H, Hayashi K, Shutoh Y, Saito TR, et al. Investiga-
tion of the chemical-induced selective type II (TH2) allergic response in mice:
effect of the length of the sensitizing phase. J Immunotoxicol (2009) 6(2):75–83.
doi:10.1080/15476910902891319
63. Dearman RJ, Basketter DA, Kimber I. Selective induction of type 2 cytokines
following topical exposure of mice to platinum salts. Food Chem Toxicol (1998)
36(3):199–207. doi:10.1016/S0278-6915(97)00143-9
64. Jotwani R, Pulendran B, Agrawal S, Cutler CW. Human dendritic cells respond
to Porphyromonas gingivalis LPS by promoting a Th2 effector response in vitro.
Eur J Immunol (2003) 33(11):2980–6. doi:10.1002/eji.200324392
65. Salgame P, Yap GS, Gause WC. Effect of helminth-induced immunity on
infections with microbial pathogens. Nat Immunol (2013) 14(11):1118–26.
doi:10.1038/ni.2736
66. Bryson K, Besteiro S, McGachy HA, Coombs GH, Mottram JC, Alexander J.
Overexpression of the natural inhibitor of cysteine peptidases in Leishmania
mexicana leads to reduced virulence and a Th1 response. Infect Immun (2009)
77(7):2971–8. doi:10.1128/IAI.00558-08
67. Kuroda E, Ishii KJ, Uematsu S, Ohata K, Coban C, Akira S, et al. Silica
crystals and aluminum salts regulate the production of prostaglandin in
macrophages via NALP3 inflammasome-independent mechanisms. Immunity
(2011) 34(4):514–26. doi:10.1016/j.immuni.2011.03.019
68. Mishra PK, Wu W, Rozo C, Hallab NJ, Benevenia J, Gause WC. Micrometer-
sized titanium particles can induce potent Th2-type responses through
TLR4-independent pathways. J Immunol (2011) 187(12):6491–8. doi:10.4049/
jimmunol.1101392
69. Kool M, Willart MAM, van Nimwegen M, Bergen I, Pouliot P, Virchow JC, et al.
An unexpected role for uric acid as an inducer of T helper 2 cell immunity
to inhaled antigens and inflammatory mediator of allergic asthma. Immunity
(2011) 34(4):527–40. doi:10.1016/j.immuni.2011.03.015
70. Marichal T, Ohata K, Bedoret D, Mesnil C, Sabatel C, Kobiyama K, et al. DNA
released from dying host cells mediates aluminum adjuvant activity. Nat Med
(2011) 17(8):996–1002. doi:10.1038/nm.2403
71. Kouzaki H, Iijima K, Kobayashi T, O’Grady SM, Kita H. The danger sig-
nal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-
33 release and innate Th2-type responses. J Immunol (2011) 186(7):4375–87.
doi:10.4049/jimmunol.1003020
72. Tang H, Cao W, Kasturi SP, Ravindran R, Nakaya HI, Kundu K, et al. The T
helper type 2 response to cysteine proteases requires dendritic cell-basophil
cooperation via ROS-mediated signaling. Nat Immunol (2010) 11(7):608–17.
doi:10.1038/ni.1883
73. Moghaddam AE, Gartlan KH, Kong L, Sattentau QJ. Reactive carbonyls are
a major Th2-inducing damage-associated molecular pattern generated by
oxidative stress. J Immunol (2011) 187(4):1626–33. doi:10.4049/jimmunol.
1003906
74. Chavanas S, Bodemer C, Rochat A, Hamel-Teillac D, Ali M, Irvine AD, et al.
Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton
syndrome. Nat Genet (2000) 25(2):141–2. doi:10.1038/75977
75. Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B, Lawrence R, et al. Gene
polymorphism in Netherton and common atopic disease. Nat Genet (2001)
29(2):175–8. doi:10.1038/ng728
76. Briot A, Deraison C, Lacroix M, Bonnart C, Robin A, Besson C, et al. Kallikrein
5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stro-
mal lymphopoietin expression in Netherton syndrome. J Exp Med (2009)
206(5):1135–47. doi:10.1084/jem.20082242
77. Fritz JH, Le Bourhis L, Sellge G, Magalhaes JG, Fsihi H, Kufer TA, et al. Nod1-
mediated innate immune recognition of peptidoglycan contributes to the onset
of adaptive immunity. Immunity (2007) 26(4):445–59. doi:10.1016/j.immuni.
2007.03.009
78. Magalhaes JG, Fritz JH, Le Bourhis L, Sellge G, Travassos LH, Selvanan-
tham T, et al. Nod2-dependent Th2 polarization of antigen-specific immunity.
J Immunol (2008) 181(11):7925–35. doi:10.4049/jimmunol.181.11.7925
79. Magalhaes JG, Rubino SJ, Travassos LH, Le Bourhis L, Duan W, Sellge G, et al.
Nucleotide oligomerization domain-containing proteins instruct T cell helper
type 2 immunity through stromal activation. Proc Natl Acad Sci U S A (2011)
108(36):14896–901. doi:10.1073/pnas.1015063108
80. Eisenbarth SC, Piggott DA, Huleatt JW, Visintin I, Herrick CA, Bottomly K.
Lipopolysaccharide-enhanced, Toll-like receptor 4-dependent T helper cell
type 2 responses to inhaled antigen. J Exp Med (2002) 196(12):1645–51.
doi:10.1084/jem.20021340
81. Tan AM, Chen HC, Pochard P, Eisenbarth SC, Herrick CA, Bottomly HK. TLR4
signaling in stromal cells is critical for the initiation of allergic Th2 responses
to inhaled antigen. J Immunol (2010) 184(7):3535–44. doi:10.4049/jimmunol.
0900340
82. Agrawal S, Agrawal A, Doughty B, Gerwitz A, Blenis J, Van Dyke T, et al.
Cutting edge: different toll-like receptor agonists instruct dendritic cells to
induce distinct Th responses via differential modulation of extracellular signal-
regulated kinase-mitogen-activated protein kinase and c-Fos. J Immunol (2003)
171(10):4984–9. doi:10.4049/jimmunol.171.10.4984
83. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht
BN. House dust mite allergen induces asthma via Toll-like receptor 4
triggering of airway structural cells. Nat Med (2009) 15(4):410–6. doi:10.1038/
nm.1946
Frontiers in Immunology | Tumor Immunity July 2014 | Volume 5 | Article 347 | 16
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dalessandri and Strid Type 2 immunity regulate tissue homeostasis
84. Schmidt M, Raghavan B, Müller V, Vogl T, Fejer G, Tchaptchet S, et al. Crucial
role for human Toll-like receptor 4 in the development of contact allergy to
nickel. Nat Immunol (2010) 11(9):814–9. doi:10.1038/ni.1919
85. Wen L, Roberts SJ,Viney JL,Wong FS, Mallick C, Findly RC, et al. Immunoglob-
ulin synthesis and generalized autoimmunity in mice congenitally deficient in
alpha beta(+) T cells. Nature (1994) 369(6482):654–8. doi:10.1038/369654a0
86. Wen L, Pao W, Wong FS, Peng Q, Craft J, Zheng B, et al. Germinal cen-
ter formation, immunoglobulin class switching, and autoantibody produc-
tion driven by “non alpha/beta” T cells. J Exp Med (1996) 183(5):2271–82.
doi:10.1084/jem.183.5.2271
87. Aguado E, Richelme S, Nuñez-Cruz S, Miazek A, Mura A-M, Richelme M, et al.
Induction of T helper type 2 immunity by a point mutation in the LAT adaptor.
Science (2002) 296(5575):2036–40. doi:10.1126/science.1069057
88. Qi Q, Xia M, Hu J, Hicks E, Iyer A, Xiong N, et al. Enhanced development of
CD4+ gammadelta T cells in the absence of Itk results in elevated IgE produc-
tion. Blood (2009) 114(3):564–71. doi:10.1182/blood-2008-12-196345
89. Felices M, Yin CC, Kosaka Y, Kang J, Berg LJ. Tec kinase Itk in gamma delta T
cells is pivotal for controlling IgE production in vivo. Proc Natl Acad Sci U S A
(2009) 106(20):8308–13. doi:10.1073/pnas.0808459106
90. McCoy KD, Harris NL, Diener P, Hatak S, Odermatt B, Hangartner L, et al.
Natural IgE production in the absence of MHC class II cognate help. Immunity
(2006) 24(3):329–39. doi:10.1016/j.immuni.2006.01.013
91. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Ned Tijdschr
Geneeskd (1909) 5:273–90.
92. Burnet M. Cancer; a biological approach. I. The processes of control. Br Med J
(1957) 1(5022):779–86. doi:10.1136/bmj.1.5022.779
93. Burnet M. Cancer: a biological approach. III. Viruses associated with neo-
plastic conditions. IV. Practical applications. Br Med J (1957) 1(5023):841–7.
doi:10.1136/bmj.1.5023.841
94. Thomas L. On immunosurveillance in human cancer. Yale J Biol Med (1982)
55(3–4):329–33.
95. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu
Rev Immunol (2004) 22(1):329–60. doi:10.1146/annurev.immunol.22.012703.
104803
96. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and
resistance to rejection of tumor cells expressing dominant negative IFN gamma
receptors. Immunity (1994) 1(6):447–56. doi:10.1016/1074-7613(94)90087-6
97. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demon-
stration of an interferon gamma-dependent tumor surveillance system in
immunocompetent mice. Proc Natl Acad Sci U S A (1998) 95(13):7556–61.
doi:10.1073/pnas.95.13.7556
98. Shankaran V, Ikeda H, Bruce AT, White JM. IFNγ and lymphocytes prevent pri-
mary tumour development and shape tumour immunogenicity. Nature (2001)
410(6832):1107–11. doi:10.1038/35074122
99. Smyth MJ, Thia KY, Street SE, Cretney E, Trapani JA, Taniguchi M, et al. Dif-
ferential tumor surveillance by natural killer (NK) and NKT cells. J Exp Med
(2000) 191(4):661–8. doi:10.1084/jem.191.4.661
100. Girardi M, Oppenheim DE, Steele CR, Lewis JM, Glusac E, Filler R, et al.
Regulation of cutaneous malignancy by gamma delta T cells. Science (2001)
294(5542):605–9. doi:10.1126/science.1063916
101. DePinho RA. The age of cancer. Nature (2000) 408(6809):248–54. doi:10.1038/
35041694
102. Matzinger P. The danger model: a renewed sense of self. Science (2002)
296(5566):301–5. doi:10.1126/science.1071059
103. Chao MP, Majeti R, Weissman IL. Programmed cell removal: a new obsta-
cle in the road to developing cancer. Nat Rev Cancer (2012) 12(1):58–67.
doi:10.1038/nrc3171
104. Ma Y, Galluzzi L, Zitvogel L, Kroemer G. Autophagy and cellular immune
responses. Immunity (2013) 39(2):211–27. doi:10.1016/j.immuni.2013.07.017
105. Zitvogel L, Kepp O, Galluzzi L, Kroemer G. Inflammasomes in carcinogen-
esis and anticancer immune responses. Nat Immunol (2012) 13(4):343–51.
doi:10.1038/ni.2224
106. Schonthaler HB, Guinea-Viniegra J, Wculek SK, Ruppen I, Ximénez-Embún
P, Guío-Carrión A, et al. S100A8-S100A9 protein complex mediates psoria-
sis by regulating the expression of complement factor C3. Immunity (2013)
39(6):1171–81. doi:10.1016/j.immuni.2013.11.011
107. Ullrich E, Koch J, Cerwenka A, Steinle A. New prospects on
the NKG2D/NKG2DL system for oncology. Oncoimmunology (2013)
2(10):e26097. doi:10.4161/onci.26097
108. Cerwenka A, Lanier LL. NKG2D ligands: unconventional MHC class I-like mol-
ecules exploited by viruses and cancer. Tissue Antigens (2003) 61(5):335–43.
doi:10.1034/j.1399-0039.2003.00070.x
109. Van Belle TL, von Herrath MG. The role of the activating receptor NKG2D in
autoimmunity. Mol Immunol (2009) 47(1):8–11. doi:10.1016/j.molimm.2009.
02.023
110. Suárez-Alvarez B, López-Vázquez A, Baltar JM, Ortega F, López-Larrea C.
Potential role of NKG2D and its ligands in organ transplantation: new tar-
get for immunointervention. Am J Transplant (2009) 9(2):251–7. doi:10.1111/
j.1600-6143.2008.02526.x
111. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair
expression of NKG2D and T-cell activation. Nature (2002) 419(6908):734–8.
doi:10.1038/nature01112
112. Lodoen MB, Lanier LL. Viral modulation of NK cell immunity. Nat Rev Micro-
biol (2005) 3(1):59–69. doi:10.1038/nrmicro1066
113. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune
responses. Immunol Rev (2010) 235(1):267–85. doi:10.1111/j.0105-2896.2010.
00893.x
114. Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, et al. Acute upreg-
ulation of an NKG2D ligand promotes rapid reorganization of a local immune
compartment with pleiotropic effects on carcinogenesis. Nat Immunol (2008)
9(2):146–54. doi:10.1038/ni1556
115. Strid J, Tigelaar RE, Hayday AC. Skin immune surveillance by T cells – a new
order? Semin Immunol (2009) 21(3):110–20. doi:10.1016/j.smim.2009.03.002
116. Hayday AC. Gammadelta T cells and the lymphoid stress-surveillance response.
Immunity (2009) 31(2):184–96. doi:10.1016/j.immuni.2009.08.006
117. Takai Y, Irie K, Shimizu K, Sakisaka T, Ikeda W. Nectins and nectin-like mol-
ecules: roles in cell adhesion, migration, and polarization. Cancer Sci (2003)
94(8):655–67. doi:10.1111/j.1349-7006.2003.tb01499.x
118. Giangreco A, Jensen KB, Takai Y, Miyoshi J, Watt FM. Necl2 regulates epi-
dermal adhesion and wound repair. Development (2009) 136(20):3505–14.
doi:10.1242/dev.038232
119. Chan CJ, Andrews DM, Smyth MJ. Receptors that interact with nectin and
nectin-like proteins in the immunosurveillance and immunotherapy of cancer.
Curr Opin Immunol (2012) 24(2):246–51. doi:10.1016/j.coi.2012.01.009
120. Soriani A, Zingoni A, Cerboni C, Iannitto ML, Ricciardi MR, Di Gialleonardo
V, et al. ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands
on multiple myeloma cells by therapeutic agents results in enhanced NK-
cell susceptibility and is associated with a senescent phenotype. Blood (2009)
113(15):3503–11. doi:10.1182/blood-2008-08-173914
121. Shibuya A, Campbell D, Hannum C, Yssel H, Franz-Bacon K, McClanahan T,
et al. DNAM-1, a novel adhesion molecule involved in the cytolytic function
of T lymphocytes. Immunity (1996) 4(6):573–81. doi:10.1016/S1074-7613(00)
70060-4
122. Ramsbottom KM, Hawkins ED, Shimoni R, McGrath M, Chan CJ, Russell SM,
et al. Cutting edge: DNAX accessory molecule 1-deficient CD8+ T cells display
immunological synapse defects that impair antitumor immunity. J Immunol
(2014) 192(2):553–7. doi:10.4049/jimmunol.1302197
123. Takahashi Y, Iwai M, Kawai T, Arakawa A, Ito T, Sakurai-Yageta M, et al. Aber-
rant expression of tumor suppressors CADM1 and 4.1B in invasive lesions
of primary breast cancer. Breast Cancer (2012) 19(3):242–52. doi:10.1007/
s12282-011-0272-7
124. Witherden DA, Verdino P, Rieder SE, Garijo O, Mills RE, Teyton L, et al.
The junctional adhesion molecule JAML is a costimulatory receptor for
epithelial gamma delta T cell activation. Science (2010) 329(5996):1205–10.
doi:10.1126/science.1192698
125. Verdino P, Witherden DA, Havran WL, Wilson IA. The molecular interaction of
CAR and JAML recruits the central cell signal transducer PI3K. Science (2010)
329(5996):1210–4. doi:10.1126/science.1187996
126. Witherden DA, Watanabe M, Garijo O, Rieder SE, Sarkisyan G, Cronin SJF,
et al. The CD100 receptor interacts with its plexin B2 ligand to regulate epider-
mal γδ T cell function. Immunity (2012) 37(2):314–25. doi:10.1016/j.immuni.
2012.05.026
127. Meehan TF, Witherden DA, Kim C-H, Sendaydiego K, Ye I, Garijo O, et al. Pro-
tection against colitis by CD100-dependent modulation of intraepithelial γδ T
lymphocyte function. Mucosal Immunol (2014) 7(1):134–42. doi:10.1038/mi.
2013.32
128. Shi W, Kumanogoh A, Watanabe C, Uchida J, Wang X, Yasui T, et al. The
class IV semaphorin CD100 plays nonredundant roles in the immune system:
www.frontiersin.org July 2014 | Volume 5 | Article 347 | 17
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dalessandri and Strid Type 2 immunity regulate tissue homeostasis
defective B and T cell activation in CD100-deficient mice. Immunity (2000)
13(5):633–42. doi:10.1016/S1074-7613(00)00063-7
129. Park O, Jeong W-I,Wang L,Wang H, Lian Z-X, Gershwin ME, et al. Diverse roles
of invariant natural killer T cells in liver injury and fibrosis induced by carbon
tetrachloride. Hepatology (2009) 49(5):1683–94. doi:10.1002/hep.22813
130. Sagiv A, Biran A, Yon M, Simon J, Lowe SW, Krizhanovsky V. Granule exo-
cytosis mediates immune surveillance of senescent cells. Oncogene (2013)
32(15):1971–7. doi:10.1038/onc.2012.206
131. Devey L, Ferenbach D, Mohr E, Sangster K, Bellamy CO, Hughes J, et al. Tissue-
resident macrophages protect the liver from ischemia reperfusion injury via
a heme oxygenase-1-dependent mechanism. Mol Ther (2009) 17(1):65–72.
doi:10.1038/mt.2008.237
132. Girardi M, Lewis J, Glusac E, Filler RB, Geng L, Hayday AC, et al. Resident
skin-specific gamma delta T cells provide local, non-redundant regulation of
cutaneous inflammation. J Exp Med (2002) 195(7):855–67. doi:10.1084/jem.
20012000
133. Girardi M, Lewis JM, Filler RB, Hayday AC, Tigelaar RE. Environmentally
responsive and reversible regulation of epidermal barrier function by γδ T
cells. J Invest Dermatol (2006) 126(4):808–14. doi:10.1038/sj.jid.5700120
134. Sharp LL, Jameson JM, Cauvi G, Havran WL. Dendritic epidermal T cells regu-
late skin homeostasis through local production of insulin-like growth factor 1.
Nat Immunol (2005) 6(1):73–9. doi:10.1038/ni1152
135. Jameson J, Havran WL. Skin gammadelta T-cell functions in homeostasis and
wound healing. Immunol Rev (2007) 215:114–22. doi:10.1111/j.1600-065X.
2006.00483.x
136. Jameson J, Ugarte K, Chen N, Yachi P, Fuchs E, Boismenu R, et al. A role for
skin gamma delta T cells in wound repair. Science (2002) 296(5568):747–9.
doi:10.1126/science.1069639
137. Chen Y, Chou K, Fuchs E, Havran WL, Boismenu R. Protection of the intestinal
mucosa by intraepithelial gamma delta T cells. Proc Natl Acad Sci U S A (2002)
99(22):14338–43. doi:10.1073/pnas.212290499
138. Senovilla L, Galluzzi L, Zitvogel L, Kroemer G. Immunosurveillance as
a regulator of tissue homeostasis. Trends Immunol (2013) 34(10):471–81.
doi:10.1016/j.it.2013.06.005
139. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adap-
tive immunity to cancer. Annu Rev Immunol (2011) 29(1):235–71. doi:10.1146/
annurev-immunol-031210-101324
140. Dunham LJ. Cancer in man at site of prior benign lesion of skin or mucous
membrane: a review. Cancer Res (1972) 32(7):1359–74.
141. Walter ND, Rice PL, Redente EF, Kauvar EF, Lemond L,Aly T, et al. Wound heal-
ing after trauma may predispose to lung cancer metastasis: review of potential
mechanisms. Am J Respir Cell Mol Biol (2011) 44(5):591–6. doi:10.1165/rcmb.
2010-0187RT
142. Ortiz-Urda S. Type VII collagen is required for ras-driven human epidermal
tumorigenesis. Science (2005) 307(5716):1773–6. doi:10.1126/science.1106209
143. South AP, O’Toole EA. Understanding the pathogenesis of recessive dys-
trophic epidermolysis bullosa squamous cell carcinoma. Dermatol Clin (2010)
28(1):171–8. doi:10.1016/j.det.2009.10.023
144. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor
stroma generation and wound healing. N Engl J Med (1986) 315(26):1650–9.
doi:10.1056/NEJM198612253152606
145. Coussens LM, Zitvogel L, Palucka AK. Neutralizing tumor-promoting chronic
inflammation: a magic bullet? Science (2013) 339(6117):286–91. doi:10.1126/
science.1232227
146. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet
(2001) 357(9255):539–45. doi:10.1016/S0140-6736(00)04046-0
147. Farhadi N, Lambert L, Triulzi C, Openshaw PJ, Guerra N. Natural killer cell
NKG2D and granzyme B are critical for allergic pulmonary inflammation.
J Allergy Clin Immunol (2014) 133(3):827–35. doi:10.1016/j.jaci.2013.09.048
148. Oh M-H, Oh SY, Yu J, Myers AC, Leonard WJ, Liu YJ, et al. IL-13 induces
skin fibrosis in atopic dermatitis by thymic stromal lymphopoietin. J Immunol
(2011) 186(12):7232–42. doi:10.4049/jimmunol.1100504
149. Wilson SR, Thé L, Batia LM, Beattie K, Katibah GE, McClain SP, et al. The
epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to
induce itch. Cell (2013) 155(2):285–95. doi:10.1016/j.cell.2013.08.057
150. Metz M, Piliponsky AM, Chen CC, Lammel V, Abrink M, Pejler G, et al. Mast
cells can enhance resistance to snake and honeybee venoms. Science (2006)
313(5786):526–30. doi:10.1126/science.1128877
151. Schneider LA, Schlenner SM, Feyerabend TB, Wunderlin M, Rodewald H-R.
Molecular mechanism of mast cell mediated innate defense against endothelin
and snake venom sarafotoxin. J Exp Med (2007) 204(11):2629–39. doi:10.1084/
jem.20071262
152. Matsuda H, Watanabe N, Kiso Y, Hirota S, Ushio H, Kannan Y, et al. Neces-
sity of IgE antibodies and mast cells for manifestation of resistance against
larval Haemaphysalis longicornis ticks in mice. J Immunol (1990) 144(1):
259–62.
153. Pearce EJ, Cheever A, Leonard S, Covalesky M, Fernandez-Botran R, Kohler
G, et al. Schistosoma mansoni in IL-4-deficient mice. Int Immunol (1996)
8(4):435–44. doi:10.1093/intimm/8.4.435
154. Gause WC, Wynn TA, Allen JE. Type 2 immunity and wound healing: evo-
lutionary refinement of adaptive immunity by helminths. Nat Rev Immunol
(2013) 13(8):607–14. doi:10.1038/nri3476
155. Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CGK, Doering
TA, et al. Innate lymphoid cells promote lung-tissue homeostasis after infec-
tion with influenza virus. Nat Immunol (2011) 12(11):1045–54. doi:10.1031/
ni.2131
156. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health
and disease. Nat Rev Immunol (2013) 13(1):9–22. doi:10.1038/nri3341
157. Okumura S, Sagara H, Fukuda T, Saito H, Okayama Y. FceRI-mediated
amphiregulin production by human mast cells increases mucin gene expres-
sion in epithelial cells. J Allergy Clin Immunol (2005) 115(2):272–9. doi:10.
1016/j.jaci.2004.12.835
158. Arwert EN, Hoste E, Watt FM. Epithelial stem cells, wound healing and cancer.
Nat Rev Cancer (2012) 12(3):170–80. doi:10.1038/nrc3217
159. Conticello C, Pedini F, Zeuner A, Patti M, Zerilli M, Stassi G, et al. IL-
4 protects tumor cells from anti-CD95 and chemotherapeutic agents via
up-regulation of antiapoptotic proteins. J Immunol (2004) 172(9):5467–77.
doi:10.4049/jimmunol.172.9.5467
160. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker
M, et al. Treatment of established renal cancer by tumor cells engineered to
secrete interleukin-4. Science (1991) 254(5032):713–6. doi:10.1126/science.
1948050
161. Hock H, Dorsch M, Kunzendorf U, Qin Z, Diamantstein T, Blankenstein
T. Mechanisms of rejection induced by tumor cell-targeted gene transfer of
interleukin 2, interleukin 4, interleukin 7, tumor necrosis factor, or inter-
feron gamma. Proc Natl Acad Sci U S A (1993) 90(7):2774–8. doi:10.1073/
pnas.90.7.2774
162. Pericle F, Giovarelli M, Colombo MP, Ferrari G, Musiani P, Modesti A, et al. An
efficient Th2-type memory follows CD8+ lymphocyte-driven and eosinophil-
mediated rejection of a spontaneous mouse mammary adenocarcinoma engi-
neered to release IL-4. J Immunol (1994) 153(12):5659–73.
163. Rodolfo M, Zilocchi C, Accornero P, Cappetti B, Arioli I, Colombo MP. IL-4-
transduced tumor cell vaccine induces immunoregulatory type 2 CD8 T lym-
phocytes that cure lung metastases upon adoptive transfer. J Immunol (1999)
163(4):1923–8.
164. Ellyard JI, Simson L, Parish CR. Th2-mediated anti-tumour immunity: friend
or foe? Tissue Antigens (2007) 70(1):1–11. doi:10.1111/j.1399-0039.2007.
00869.x
165. Chen S-F, Nieh S, Jao S-W, Wu M-Z, Liu C-L, Chang Y-C, et al. The paracrine
effect of cancer-associated fibroblast-induced interleukin-33 regulates the
invasiveness of head and neck squamous cell carcinoma. J Pathol (2013)
231(2):180–9. doi:10.1002/path.4226
166. Pedroza-Gonzalez A, Xu K, Wu T-C, Aspord C, Tindle S, Marches F, et al.
Thymic stromal lymphopoietin fosters human breast tumor growth by pro-
moting type 2 inflammation. J Exp Med (2011) 208(3):479–90. doi:10.1084/
jem.20102131
167. Hallett MA, Venmar KT, Fingleton B. Cytokine stimulation of epithelial cancer
cells: the similar and divergent functions of IL-4 and IL-13. Cancer Res (2012)
72(24):6338–43. doi:10.1158/0008-5472.CAN-12-3544
168. Renard N, Duvert V, Banchereau J, Saeland S. Interleukin-13 inhibits the pro-
liferation of normal and leukemic human B-cell precursors. Blood (1994)
84(7):2253–60.
169. Blais Y, Gingras S, Haagensen DE, Labrie F, Simard J. Interleukin-4 and
interleukin-13 inhibit estrogen-induced breast cancer cell proliferation and
stimulate GCDFP-15 expression in human breast cancer cells. Mol Cell
Endocrinol (1996) 121(1):11–8. doi:10.1016/0303-7207(96)03843-9
Frontiers in Immunology | Tumor Immunity July 2014 | Volume 5 | Article 347 | 18
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dalessandri and Strid Type 2 immunity regulate tissue homeostasis
170. Obiri NI, Husain SR, Debinski W, Puri RK. Interleukin 13 inhibits growth
of human renal cell carcinoma cells independently of the p140 interleukin 4
receptor chain. Clin Cancer Res (1996) 2(10):1743–9.
171. Fujisawa T, Joshi BH, Puri RK. IL-13 regulates cancer invasion and metastasis
through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian
cancer. Int J Cancer (2012) 131(2):344–56. doi:10.1002/ijc.26366
172. Simson L, Ellyard JI, Dent LA, Matthaei KI, Rothenberg ME, Foster PS,
et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for
eosinophils in tumor immune surveillance. J Immunol (2007) 178(7):4222–9.
doi:10.4049/jimmunol.178.7.4222
173. Dalton DK, Noelle RJ. The roles of mast cells in anticancer immunity.
Cancer Immunol Immunother (2012) 61(9):1511–20. doi:10.1007/s00262-012-
1246-0
174. Vernersson M, Aveskogh M, Hellman L. Cloning of IgE from the echidna
(Tachyglossus aculeatus) and a comparative analysis of epsilon chains from
all three extant mammalian lineages. Dev Comp Immunol (2004) 28(1):61–75.
doi:10.1016/S0145-305X(03)00084-3
175. Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron
M, et al. AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy
(2008) 63(10):1255–66. doi:10.1111/j.1398-9995.2008.01768.x
176. Reali E, Greiner JW, Corti A, Gould HJ, Bottazzoli F, Paganelli G, et al. IgEs tar-
geted on tumor cells: therapeutic activity and potential in the design of tumor
vaccines. Cancer Res (2001) 61(14):5517–22.
177. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, et al. IgG4 sub-
class antibodies impair antitumor immunity in melanoma. J Clin Invest (2013)
123(4):1457–74. doi:10.1172/JCI65579
178. Olver S, Groves P, Buttigieg K, Morris ES, Janas ML, Kelso A, et al. Tumor-
derived interleukin-4 reduces tumor clearance and deviates the cytokine
and granzyme profile of tumor-induced CD8+ T cells. Cancer Res (2006)
66(1):571–80. doi:10.1158/0008-5472.CAN-05-1362
179. Lebel-Binay S, Laguerre B, Quintin-Colonna F, Conjeaud H, Magazin M,
Miloux B, et al. Experimental gene therapy of cancer using tumor cells
engineered to secrete interleukin-13. Eur J Immunol (1995) 25(8):2340–8.
doi:10.1002/eji.1830250833
180. Skinnider BF, Elia AJ, Gascoyne RD, Patterson B, Trumper L, Kapp U, et al.
Signal transducer and activator of transcription 6 is frequently activated
in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood (2002)
99(2):618–26. doi:10.1182/blood.V99.2.618
181. Jovanovic I, Radosavljevic G, Mitrovic M, Juranic VL, McKenzie ANJ, Arseni-
jevic N, et al. ST2 deletion enhances innate and acquired immunity to murine
mammary carcinoma. Eur J Immunol (2011) 41(7):1902–12. doi:10.1002/eji.
201141417
182. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic
MZ, Arsenijevic NN, et al. Interleukin-33/ST2 axis promotes breast can-
cer growth and metastases by facilitating intratumoral accumulation
of immunosuppressive and innate lymphoid cells. Int J Cancer (2013)
134(7):1669–82. doi:10.1002/ijc.28481
183. Villarreal D, Wise MC, Walters JN, Reuschel E, Choi MJ, Obeng-Adjei N,
et al. Alarmin IL-33 acts as an immunoadjuvant to enhance antigen-specific
tumor immunity. Cancer Res (2014) 74(6):1–12. doi:10.1158/0008-5472.CAN-
13-2729
184. Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG,
et al. Antitumor IgE adjuvanticity: key role of Fc RI. J Immunol (2009)
183(7):4530–6. doi:10.4049/jimmunol.0900842
185. McWhorter WP. Allergy and risk of cancer. A prospective study using
NHANESI follow up data. Cancer (1988) 62(2):451–5. doi:10.1002/1097-
0142(19880715)62:2<451::AID-CNCR2820620234>3.0.CO;2-D
186. Josephs DH, Spicer JF, Corrigan CJ, Gould HJ, Karagiannis SN. Epidemiological
associations of allergy, IgE and cancer. Clin Exp Allergy (2013) 43(10):1110–23.
doi:10.1111/cea.12178
187. Sherman PW, Holland E, Sherman JS. Allergies: their role in cancer prevention.
Q Rev Biol (2008) 83(4):339–62. doi:10.1086/592850
188. Rittmeyer D, Lorentz A. Relationship between allergy and cancer: an overview.
Int Arch Allergy Immunol (2012) 159(3):216–25. doi:10.1159/000338994
189. Engkilde K, Thyssen JP, Menné T, Johansen JD. Association between can-
cer and contact allergy: a linkage study. BMJ Open (2011) 1(1):e000084.
doi:10.1136/bmjopen-2011-000084
190. Van Hemelrijck M, Garmo H, Binda E, Hayday A, Karagiannis SN, Hammar N,
et al. Immunoglobulin E and cancer: a meta-analysis and a large Swedish cohort
study. Cancer Causes Control (2010) 21(10):1657–67. doi:10.1007/s10552-010-
9594-6
191. Lindelof B, Granath F, Tengvall-Linder M, Ekbom A. Allergy and cancer. Allergy
(2005) 60(9):1116–20. doi:10.1111/j.1398-9995.2005.00808.x
Conflict of Interest Statement: The Guest Associate Editor Fang-Ping Huang
declares that, despite being affiliated to the same institution as authors Tim Dalessan-
dri and Jessica Strid, the review process was handled objectively and no conflict of
interest exists. The authors declare that the research was conducted in the absence
of any commercial or financial relationships that could be construed as a potential
conflict of interest.
Received: 10 March 2014; accepted: 08 July 2014; published online: 22 July 2014.
Citation: Dalessandri T and Strid J (2014) Beneficial autoimmunity at body surfaces –
immune surveillance and rapid type 2 immunity regulate tissue homeostasis and cancer.
Front. Immunol. 5:347. doi: 10.3389/fimmu.2014.00347
This article was submitted to Tumor Immunity, a section of the journal Frontiers in
Immunology.
Copyright © 2014 Dalessandri and Strid. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use, dis-
tribution or reproduction in other forums is permitted, provided the original author(s)
or licensor are credited and that the original publication in this journal is cited, in
accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
www.frontiersin.org July 2014 | Volume 5 | Article 347 | 19
